

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 1 193 268 A1

(12) EUROPEAN PATENT APPLICATION

(43) Date of publication:  
03.04.2002 Bulletin 2002/14

(51) Int Cl.7: C07D 409/12, A61K 31/4535,  
A61K 31/55, A61K 31/4025,  
A61P 25/00, A61P 25/16,  
A61P 11/06, C07D 333/34,  
C07D 409/14, C07D 413/14

(21) Application number: 00810887.0

(22) Date of filing: 27.09.2000

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE  
Designated Extension States:  
AL LT LV MK RO SI

- Camps, Montserrat  
1290 Versoix (CH)
- Rueckle, Thomas  
1228 Plan-les-Outes (CH)
- Gotteland, Jean Pierre  
74160 Beaumont (FR)
- Biamonte, Marco  
1227 Carouge (CH)
- Arkinstall, Stephen  
Belmont, MA 02478 (US)


(71) Applicant: Applied Research Systems ARS  
Holding N.V.  
Curacao (AN)

(74) Representative: Moinas, Michel et al  
MOINAS SAVOYE & CRONIN,  
42 rue Plantamour  
1201 Genève (CH)

(72) Inventors:  
◦ Halazy, Serge  
74100 Vétraz-Monthoux (FR)  
◦ Church, Dennis  
1291 Commugny (CH)

(54) **Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Jnk kinases**

(57) The present invention is related to sulfonamide derivatives having a lipophilic moiety and which are substantially soluble under physiological conditions. Said compounds are notably for use as pharmaceutically active compounds. The present invention also related to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation.



I

The compounds of formula I according to the present invention being suitable pharmaceutical agents are those wherein

- Ar<sup>1</sup> and Ar<sup>2</sup> are independently from each other substituted or unsubstituted aryl or heteroaryl groups,
- X is O or S, preferably O;
- R<sup>1</sup> is hydrogen or a C<sub>1</sub>-C<sub>6</sub>-alkyl group, or R<sup>1</sup> forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar<sup>1</sup>;
- n is an integer from 0 to 5, preferably between 1-3 and most preferred 1;
- Y within formula I is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl which is substituted with at least one ionisable moiety to which a lipophilic chain is attached and which is containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula I thus providing a sulfonamide.

EP 1 193 268 A1

**Description**Field of the invention

5 [0001] The present invention is related to sulfonamide derivatives having a lipophilic moiety and which are substantially soluble under physiological conditions. Said sulfonamide derivatives are notably for use as pharmaceutically active compounds. Also, the present invention is related to pharmaceutical formulations containing such sulfonamide derivatives. In particular, the present invention is related to sulfonamide derivatives displaying a substantial modulatory, notably an inhibitory activity of the JNK (Jun-Kinase) function or pathways respectively, and which are therefore particularly useful in the treatment and/or prevention of disorders of the immune and the neuronal system. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation.

Background of the invention

15 [0002] Apoptosis denotes the complex contortions of the membrane and organelles of a cell as it undergoes the process of programmed cell death. During said process, the cell activates an intrinsic suicide program and systematically destroys itself. The following series of events can be observed:

- The cell surface begins to bleb and expresses pro-phagocytic signals. The whole apoptotic cell then fragments into membrane-bound vesicles that are rapidly and neatly disposed of by phagocytosis, so that there is minimal damage to the surrounding tissue.
- The cell then separates from its neighbors.

25 [0003] The nucleus also goes through a characteristic pattern of morphological changes as it commits genetic suicide, the chromatin condenses and is specifically cleaved to fragments of DNA.

[0004] Neuronal cell death plays an important role in ensuring that the nervous system develops normally. It appears that the death of developing neurons depends on the size of the target that they innervate: cells with fewer synaptic partners are more likely to die than those that have formed multiple synapses. This may reflect a process, which balances the relative number of pre- to postsynaptic neurons in the developing nervous system. Although neuronal cell death was assumed to be apoptotic, it was only recently that neurons in developing rodent brain were conclusively shown to undergo apoptosis as classified by morphology and DNA fragmentation. As cell death during development is clearly not a pathological process, it makes sense that cells actually cease to exist.

[0005] Neuronal death occurs via either apoptotic or necrotic processes following traumatic nerve injury or during neurodegenerative diseases. Multiple components are emerging as key players having a role in driving neuronal programmed cell death. Amongst the components leading to neuronal apoptosis are members of the SAPK/JNK being a sub-family of MAP Kinases (MAPKs).

[0006] MAPKs (mitogen-activated protein kinases) are serine/threonine kinases that are activated by dual phosphorylation on threonine and tyrosine residues. In mammalian cells, there are at least three separate but parallel pathways that convey information generated by extra-cellular stimuli to the MAPKs. Said pathways consist of kinase cascades leading to activation of the ERKs (extracellular regulated kinases), the JNKs (c-Jun N-terminal kinases), and the p38/CSBP kinases. While both the JNK and p38 pathways are involved in relaying stress-type extramolecular signals, the ERK pathway is primarily responsible for transducing mitogenic/differentiation signals to the cell nucleus.

[0007] SAPK cascades represent a sub-family of the mitogen-activating protein kinase family, that are activated by different external stimuli including DNA damage following UV irradiation, TNF- $\alpha$ , IL-1 $\beta$ , ceramide, cellular stress, and reactive oxygen species and have distinct substrate specificities. Signal transduction via MKK4/JNK of MKK3/p38 results in the phosphorylation of inducible transcription factors, c-Jun and ATF2, which then act as either homodimers or heterodimers to initiate transcription of down-stream effectors.

[0008] c-Jun is a protein that is forming homodimers and heterodimers (with e.g. c-Fos) to produce the transactivating complex AP-1 which is required for the activation of many genes (e.g. matrix metalloproteinases) involved in the inflammatory response. The JNKs were discovered when it was found that several different stimuli such as UV light and TNF- $\alpha$  stimulated phosphorylation of c-Jun on specific serine residues in the N-terminus of the protein.

[0009] In a recent publication of Xie X et al, (*Structure* 1998, 6 (8); 983-991) it has been suggested that activation of stress-activated signal transduction pathways are required for neuronal apoptosis induced by NGF withdrawal in rat PC-12 and superior cervical ganglia (SCG) sympathetic neuronal cells. Inhibition of specific kinases, namely MAP kinase kinase 3 (MKK3) and MAP kinase kinase 4 (MKK4), or c-Jun (part of the MKK-4 cascade) may be sufficient to block apoptosis (see also Kumagai Y et al, in *Brain Res Mol Brain Res*, 1999, 67(1), 10-17 and Yang DD et al in *Nature*, 1997, 389 (6653); 865-870). Within a few hours of NGF deprivation in SCG neurones, c-Jun becomes highly phosphorylated and protein levels increase. Similarly in rat PC-12 cells deprived of NGF, JNK and p38 undergo sus-

tained activation while ERKs are inhibited. Consistent with this JNK3 KO mice are resistant to excitotoxicity induced apoptosis in the hippocampus and more importantly they display greatly reduced epileptic like seizures in response to excitotoxicity as compared to normal animals (*Nature* 1997, 389, 865-870). More recently, it has been reported that the JNK signalling pathway is implicated in cell proliferation and could play an important role in autoimmune diseases (*Immunity*, 1998, 9, 575-585; *Current Biology*, 1999, 3, 116-125) which are mediated by T-cell activation and proliferation.

[0010] Naive (precursor) CD4<sup>+</sup> helper T (Th) cells recognise specific MHC-peptide complexes on antigen-presenting cells (APC) via the T-cell receptor (TCR) complex. In addition to the TCT-mediated signal, a co-stimulatory signal is provided at least partially by the ligation of CD28 expressed on T-cells with B7 proteins on APC. The combination of these two signals induces T-cell clonal expression.

[0011] After 4-5 days of proliferation, precursor of CD4<sup>+</sup> T cells differentiate into armed effector Th cells that mediate the functions of the immune system. During the differentiation process, substantial reprogramming of gene expression occurs.

[0012] Two subsets of effector Th cells have been defined on the basis of their distinct cytokine secretion pattern and their immuno-modulatory effects: Th1 cells produce IFN $\gamma$  and LT (TNF- $\beta$ ), which are required for cell-mediated inflammatory reactions; Th2 cells secrete IL-4, IL-5, IL-6, IL-10 and IL-13, which mediate B cell activation and differentiation. These cells play a central role in the immune response. The JNK MAP Kinase pathway is induced in Th1 but not in Th2 effector cells upon antigen stimulation. Furthermore, the differentiation of precursor CD4<sup>+</sup> T cells into effector Th1 but not Th2 cells is impaired in JNK2-deficient mice. Therefore, in recent years it has been realised that the JNK kinase pathway plays an important role in the balance of Th1 and Th2 immune response through JNK2.

[0013] With the objective of inhibiting the JNK kinase pathway, WO/9849188 teaches the use of a human polypeptide, i.e. JNK-interacting protein 1 (JIP-1), which is a biological product and which has also been assayed for overcoming apoptosis related disorders.

[0014] Although such human polypeptides have been confirmed to have an inhibitory effect onto the JNK kinase pathway, a whole variety of drawbacks are associated with their use :

- Active bio-peptides or bio-proteins are only obtained by means of rather comprehensive and expensive bio-synthesis which consequently frequently renders the resulting products fairly cost-intensive.
- The peptides are known to display poor membrane penetration and may not cross the blood brain membrane,
- The principal drawback to the use of peptide inhibitors or antagonists is the problem of low oral bioavailability resulting from intestinal degradation. Hence, they must be administered parenterally and finally,
- peptide inhibitors or antagonists are frequently viewed by the host body as intruding material to be eliminated, thus setting off an auto-immune response.

[0015] Hence, it is an objective of the present invention to provide relatively small molecules that avoid essentially all of the above-mentioned drawbacks arising from the use of peptides or proteins, however, which are suitable for the treatment of a variety of diseases, in particular of neuronal or the autoimmune system related disorders. It is notably an objective of the present invention to provide relatively small molecule chemical compounds which are able to modulate, preferably to down-regulate or to inhibit the JNK (Jun kinase) pathway so to be available as a convenient method of treating diseases which are preferably mediated by the JNK function. Moreover, it is an objective of the present invention to provide methods for preparing said small molecule chemical compounds. It is furthermore an objective of the present invention to provide a new category of pharmaceutical formulations for the treatment of diseases, preferably mediated by the JNK function. It is finally an objective of the present invention to provide a method for the treatment and/or prevention of diseases that are caused by disorders of the autoimmune and/or the neuronal system.

#### Description of the invention

[0016] The aforementioned objectives have been met according to the independent claims. Preferred embodiments are set out within the dependent claims which are incorporated herewith.

[0017] The following paragraphs provide definitions of the various chemical moieties that make up the compounds according to the invention and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader definition.

[0018] "C<sub>1</sub>-C<sub>6</sub>-alkyl" refers to monovalent alkyl groups having 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl and the like. "Aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g. phenyl) or multiple condensed rings (e.g. naphthyl). Preferred aryl include phenyl, naphthyl, phenantrenyl and the like.

[0019] "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl" refers to C<sub>1</sub>-C<sub>6</sub>-alkyl groups having an aryl substituent, including benzyl, phenethyl and the like.

**[0020]** "Heteroaryl" refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Particular examples of heteroaromatic groups include optionally substituted pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, iso-benzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinoliziny, quinazolinyl, phthalaziny, quinoxaliny, cinnolinyl, naphthyridinyl, pyrido [3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl or benzoquinolyl.

**[0021]** "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl" refers to C<sub>1</sub>-C<sub>6</sub>-alkyl groups having a heteroaryl substituent, including 2-furylmethyl, 2-thienylmethyl, 2-(1H-indol-3-yl)ethyl and the like.

**[0022]** "Alkenyl" refers to alkenyl groups preferably having from 2 to 6 carbon atoms and having at least 1 or 2 sites of alkenyl unsaturation. Preferable alkenyl groups include ethenyl (-CH=CH<sub>2</sub>), n-2-propenyl (allyl, -CH<sub>2</sub>CH=CH<sub>2</sub>) and the like.

**[0023]** "Alkynyl" refers to alkynyl groups preferably having from 2 to 6 carbon atoms and having at least 1-2 sites of alkynyl unsaturation, preferred alkynyl groups include ethynyl (-C≡CH), propargyl (-CH<sub>2</sub>C≡CH), and the like.

**[0024]** "Acy" refers to the group -C(O)R where R includes "C<sub>1</sub>-C<sub>6</sub>-alkyl", "aryl", "heteroaryl", "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl".

**[0025]** "Acyloxy" refers to the group -OC(O)R where R includes "C<sub>1</sub>-C<sub>6</sub>-alkyl", "aryl", "heteroaryl", "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl".

**[0026]** "Alkoxy" refers to the group -O-R where R includes "C<sub>1</sub>-C<sub>6</sub>-alkyl" or "aryl" or "heteroaryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl". Preferred alkoxy groups include by way of example, methoxy, ethoxy, phenoxy and the like.

**[0027]** "Alkoxy carbonyl" refers to the group -C(O)OR where R includes "C<sub>1</sub>-C<sub>6</sub>-alkyl" or "aryl" or "heteroaryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl".

**[0028]** "Aminocarbonyl" refers to the group -C(O)NRR' where each R, R' includes independently hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl or aryl or heteroaryl or "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl".

**[0029]** "Acylamino" refers to the group -NR(CO)R' where each R, R' is independently hydrogen or "C<sub>1</sub>-C<sub>6</sub>-alkyl" or "aryl" or "heteroaryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl".

**[0030]** "Halogen" refers to fluoro, chloro, bromo and iodo atoms.

**[0031]** "Sulfonyl" refers to group "-SO<sub>2</sub>-R" wherein R is selected from H, "aryl", "heteroaryl", "C<sub>1</sub>-C<sub>6</sub>-alkyl", "C<sub>1</sub>-C<sub>6</sub>-alkyl" substituted with halogens e.g. an -SO<sub>2</sub>-CF<sub>3</sub> group, "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl".

**[0032]** "Sulfoxy" refers to a group "-S(O)-R" wherein R is selected from H, "C<sub>1</sub>-C<sub>6</sub>-alkyl", "C<sub>1</sub>-C<sub>6</sub>-alkyl" substituted with halogens e.g. an -SO-CF<sub>3</sub> group, "aryl", "heteroaryl", "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl".

**[0033]** "Thioalkoxy" refers to groups -S-R where R includes "C<sub>1</sub>-C<sub>6</sub>-alkyl" or "aryl" or "heteroaryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl" or "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl". Preferred thioalkoxy groups include thiomethoxy, thioethoxy, and the like.

**[0034]** "Substituted or unsubstituted" : Unless otherwise constrained by the definition of the individual substituent, the above set out groups, like "alkyl", "alkenyl", "alkynyl", "aryl" and "heteroaryl" etc. groups can optionally be substituted with from 1 to 5 substituents selected from the group consisting of "C<sub>1</sub>-C<sub>6</sub>-alkyl", "C<sub>1</sub>-C<sub>6</sub>-alkyl aryl", "C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl", "C<sub>2</sub>-C<sub>6</sub>-alkenyl", "C<sub>2</sub>-C<sub>6</sub>-alkynyl", primary, secondary or tertiary amino groups or quaternary ammonium moieties, "acyl", "acyloxy", "acylamino", "aminocarbonyl", "alkoxy carbonyl", "aryl", "heteroaryl", carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, alkoxy, thioalkoxy, trihalomethyl and the like. Alternatively said substitution could also comprise situations where neighboring substituents have undergone ring closure, notably when vicinal functional substituents are involved, thus forming e.g. lactams, lactones, cyclic anhydrides, but also acetals, thio-acetals, amins formed by ring closure for instance in an effort to obtain a protective group.

**[0035]** "Pharmaceutically acceptable salts or complexes" refers to salts or complexes of the below-identified compounds of formula I that retain the desired biological activity. Examples of such salts include, but are not restricted to acid addition salts formed with inorganic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pantoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, naphthalene disulfonic acid, and polygalacturonic acid. Said compounds can also be administered as pharmaceutically acceptable quaternary salts known by a person skilled in the art, which specifically include the quaternary ammonium salt of the formula -NR<sub>1</sub>R<sub>2</sub>R<sub>3</sub>R<sub>4</sub> + Z<sup>-</sup>, wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> is independently hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, fumarate, citrate, tartrate, ascorbate, cinnamate, mandelate, and diphenylacetate).

**[0036]** "Pharmaceutically active derivative" refers to any compound that upon administration to the recipient, is capable of providing directly or indirectly, the activity disclosed herein.

**[0037]** "Ionisable moiety" refers to functional groups, wherein its characteristic electron distribution confers to said moiety its capacity to be transformed under physiological conditions (pH of about 7.4) into an ionic or ionised group,

or in other words into a salt. Preferred ionisable moieties are basic groups like amines that are protonated under physiological conditions thus yielding a salt.


**[0038]** "Essentially soluble under physiological conditions" means that the compounds of the present invention display for the purpose of achieving a pharmacological effect, under a physiological pH, being at about 7.4, have a sufficient solubility. A preferred threshold is at about 50 µg/mL solvent, more preferably of at least 100 µg/mL solvent.

**[0039]** "Lipophilic chain" refers to groups which have a pronounced attraction to hydrophobic groups, substituents or compounds, notably to lipids or fatty compounds or moieties. They notably include optionally substituted C<sub>4</sub>-C<sub>18</sub>-alkyl groups or a substituted or unsubstituted alkyl-aryl group.

**[0040]** "Hydrophilic group" refers to functional groups which have a pronounced attraction to hydrophilic or polar groups, substituents or compounds or fatty compounds or moieties. They notably include carboxylates, hydroxides, sulfates or sulfonates or amines or ammonium salts.

**[0041]** "Enantiomeric excess" (ee) refers to the products that are obtained by an essentially enantiomeric synthesis or a synthesis comprising an enantioselective step, whereby a surplus of one enantiomer in the order of at least about 52% ee is yielded. In the absence of an enantiomeric synthesis, racemic products are usually obtained that do however also have the inventive set out activity as JNK 1 and/or JNK 2 and/or 3 inhibitors.

**[0042]** Quite surprisingly, it was now found that sulfonamide derivatives according to formula I are suitable pharmaceutically active agents, by effectively modulating, in particular by down-regulating inhibiting the action of JNK's, notably of JNK 1 and/or JNK 2 and/or 3.



I

**[0043]** The compounds of formula I according to the present invention being suitable pharmaceutical agents are those wherein

Ar<sup>1</sup> and Ar<sup>2</sup> are independently from each other substituted or unsubstituted aryl or heteroaryl groups.

X is O or S, preferably O.

R<sup>1</sup> is hydrogen or a C<sub>1</sub>-C<sub>6</sub>-alkyl group, preferably H, or R<sup>1</sup> forms a substituted or unsubstituted 5-6-membered saturated or non-saturated ring with Ar<sup>1</sup>.

n is an integer from 0 to 5, preferably between 1-3 and most preferred 1.

**[0044]** Y within the above formula I is a 4-12-membered saturated cyclic or bicyclic alkyl containing a nitrogen, which forms a bond with the sulfonyl group of formula I. Said 4-12-membered saturated cyclic or bicyclic alkyl is substituted with at least one ionisable moiety carrying a lipophilic chain.

**[0045]** The above mentioned ionisable moiety within L<sup>1</sup> confers a considerably improved solubility to the molecules of formula I, compared to sulfonamide compounds which do not have such moiety. This is of particular interest for pharmaceutical compounds, which are to be solubilized under physiological conditions.

**[0046]** Particularly potent compounds of formula I in respect of the inhibition of JNKs, in particular of JNK1 and/or 2 and/or 3 are those where L<sup>1</sup> also comprises a lipophilic moiety. Such lipophilic groups are believed to enter into a cavity of the enzyme to be inhibited.


**[0047]** The present invention also includes the geometrical isomers, the optical active forms, enantiomers, diastereomers of compounds according to formula I, as well as their racemates and also pharmaceutically acceptable salts as well as the pharmaceutically active derivatives of the sulfonamide derivatives of formula I.

**[0048]** Preferred Ar<sup>1</sup> and Ar<sup>2</sup> in formula I are those that are independently selected from the group comprising or consisting of phenyl, thienyl, furanyl, pyrrol, pyridyl, optionally substituted by substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, like trihalomethyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxy, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkenyl, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkynyl, amino, acylamino, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, aryl, carboxyl, cyano, halo, hydroxy, nitro, sulfonyl, sulfoxy, acyloxy, C<sub>1</sub>-C<sub>6</sub>-thioalkoxy. The most preferred Ar<sup>1</sup> is a substituted phenyl, e.g. a 4-chlorophenyl, nitrophenyl, hydroxyphenyl, alkoxy phenyl, pyridyl, 3,4-dihydroxyphenyl, thioxo-dihydropyridine or its tautomer, pyrazole while the most preferred Ar<sup>2</sup> is an unsubstituted or substituted thienyl or furanyl group.

**[0049]** Preferably, such substituents attached to said thienyl or furanyl group are hydrophilic groups which are groups conferring a better solubility to the molecules of formula I. They include notably carboxylic groups, carboxylates, carboxamides, OH, or OH carrying alkyl groups, hydrazido carbonyl groups, sulfates or sulfonates or amines or ammonium salts. Hydrophilic substituents on Ar<sup>2</sup> are of particular interest in order to further improve the solubility of the molecules of formula I.

**[0050]** Where Ar<sup>1</sup> is a 4-chlorophenyl, nitrophenyl, hydroxyphenyl, alkoxy phenyl, pyridyl, 3,4-dihydroxyphenyl, thi-

oxo-dihydropyridine or its tautomer, pyrazole group, X is preferably O, R<sup>1</sup> is hydrogen, n is 1 and Ar<sup>2</sup> is thienyl or furanyl.  
**[0051]** A particularly preferred embodiment of the present invention is related to the sulfonamide derivatives, wherein Y is a pyrrolidine, an azepan or a piperidine moiety of the below formulas.




**[0052]** In said formulas, R<sup>6</sup> is selected from the group comprising or consisting of hydrogen, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxy, OH, halogen, nitro, cyano, sulfonyl, oxo (=O), sulfoxy, acyloxy, thioalkoxy and where R<sup>6</sup> is not hydrogen, n' is an integer from 0 to 4, preferably 1 or 2, whereby at least one of L<sup>1</sup> and/or L<sup>2</sup> is an ionisable moiety to which a lipophilic chain is attached.

**[0053]** In a more preferred embodiment of the sulfonamide derivatives according to formula I, Y is a pyrrolidine, an azepan or a piperidine moiety as described above, wherein R<sup>6</sup> is H, L<sup>2</sup> is H, L<sup>1</sup> is -NR<sup>3</sup>R<sup>3</sup>, where at least one of R<sup>3</sup> and R<sup>3</sup> is not a hydrogen, but a substituent selected from the group consisting of straight or branched C<sub>4</sub>-C<sub>18</sub>-alkyl, aryl-C<sub>1</sub>-C<sub>18</sub>-alkyl, heteroaryl-C<sub>2</sub>-C<sub>18</sub>-alkyl, C<sub>1</sub>-C<sub>14</sub>-alkyl substituted with a C<sub>3</sub>-C<sub>12</sub>-cycloalkyl or -bicyclo or -tricycloalkyl, and whereby said alkyl chain may contain 1-3 O or S atoms.

**[0054]** More preferred L<sup>1</sup> is -NHR<sup>3</sup>, where R<sup>3</sup> is a straight or branched C<sub>6</sub>-C<sub>12</sub>-alkyl, preferably a C<sub>8</sub>-C<sub>12</sub>-alkyl, optionally substituted with a cyclohexyl group.

The most preferred sulfonamide derivatives according to the present invention are those wherein, wherein Y is a piperidine group



and wherein L<sup>1</sup> is -NHR<sup>3</sup>, where R<sup>3</sup> is a straight or branched C<sub>6</sub>-C<sub>12</sub>-alkyl, preferably a C<sub>8</sub>-C<sub>12</sub>-alkyl.

**[0055]** Specific examples of compounds of formula I include the following :

3-methoxy-N-({5-({4-({4-(trifluoromethyl)benzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 4-chloro-N-({5-({4-({3-chlorobenzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 4-chloro-N-({5-({4-({4-methoxybenzyl}piperazin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({4-(trifluoromethyl)sulfonyl}benzyl)amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({4-phenoxybenzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({4-(trifluoromethyl)sulfonyl}benzyl)amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({3-methylbenzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({4-propylbenzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({3-(trifluoromethyl)benzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({4-(trifluoromethoxy)benzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 N-({5-({4-({4-(difluoromethoxy)benzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-3-methoxybenzamide  
 3-methoxy-N-({5-({4-({2,3,4,5,6-pentamethylbenzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({4-propoxybenzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 N-({5-({4-({4-butoxybenzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-3-methoxybenzamide  
 3-methoxy-N-({5-({4-({4-methoxybenzyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({pyridin-4-ylmethyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({pyridin-2-ylmethyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({pyridin-3-ylmethyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide

3-methoxy-N-[[5-({4-[(quinolin-4-ylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(4-tert-butylbenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(3-ethoxybenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 4-chloro-N-[[5-({4-(hexylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-(heptylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-(pentylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-(butylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-(dodecylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(2-cyclohexylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(cyclohexylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(1R)-1-cyclohexylethyl]amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide  
 4-chloro-N-[[5-({4-[(2-propoxyethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(1-adamantylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide  
 4-chloro-N-[[5-({4-[(2-pyridin-2-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(2-piperidin-1-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(2-ethylhexyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-(octylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide N-[[5-({4-(heptylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-(octylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-(pentylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-(butylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-(dodecylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-(nonylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-(decylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-(ethylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(2-cyclohexylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(1R)-1-cyclohexylethyl]amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-[(2-propoxyethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(1-adamantylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(3,3-diethoxypropyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-[(3-morpholin-4-ylpropyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(2-pyridin-2-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(2-piperidin-1-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(2-ethylhexyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-(hexylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-[(2-{3-(trifluoromethyl)phenyl}ethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(2-(4-methylphenyl)ethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(4-(trifluoromethyl)benzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(1S,2R)-2-phenylcyclopropyl]amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(1-naphthylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(2-phenylpropyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(2-(4-hydroxyphenyl)ethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-[(3-phenylpropyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(2,3-dihydroxypropyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(2-hydroxyethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(2-[1,1'-biphenyl]-4-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(1,1'-biphenyl)-3-ylmethyl]amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-[(2-thien-2-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 5-[(3-methoxybenzoyl)amino]methyl-2-[[4-(octylamino)piperidin-1-yl)sulfonyl]thiophene-3-carboxylic acid  
 N-[[5-({4-(heptylamino)azepan-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-(octylamino)azepan-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-(pentylamino)azepan-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-(butylamino)azepan-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-(dodecylamino)azepan-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide

- N-[(5-[(4-[(2-cyclohexylethyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(4-[(1R)-1-cyclohexylethyl]amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 5 3-methoxy-N-[(5-[(4-[(2-propoxyethyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(4-[(cyclohexylmethyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(4-[(1-adamantylmethyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[(5-[(4-[(3-morpholin-4-ylpropyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 3-methoxy-N-[(5-[(4-[(2-pyridin-2-ylethyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 10 3-methoxy-N-[(5-[(4-[(2-piperidin-1-ylethyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(4-[(2-ethylhexyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(4-[(3-(1H-imidazol-1-yl)propyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 4-chloro-N-[(5-[(4-(heptylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(4-(octylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 15 4-chloro-N-[(5-[(4-(pentylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(4-(butylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide  
 4-chloro-N-[(5-[(4-(dodecylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(4-[(2-cyclohexylethyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 20 N-[(5-[(4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide  
 4-chloro-N-[(5-[(4-[(2-propoxyethyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(4-[(2-ethylhexyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(4-(hexylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(4-(hexylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 4-chloro-N-[(5-[(4-[hexyl(pyridin-2-ylmethyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 25 4-chloro-N-[(5-[(4-[(cyclohexylmethyl)(hexyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(4-[benzyl(hexyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide  
 4-chloro-N-[(5-[(4-[hexyl(pyridin-3-ylmethyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(4-[hexyl(pyridin-4-ylmethyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(4-[(5-bromo-2-furyl)methyl](hexyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide  
 30 N-[(5-[(4-[butyl(hexyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide  
 4-chloro-N-[(5-[(4-[hexyl(3-phenylpropyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(4-[hexyl(2-phenylethyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(4-[hexyl(methyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(3-(pentylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide N-[(5-[(3-(heptylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 35 3-methoxy-N-[(5-[(3-(octylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(3-(butylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(3-(dodecylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(3-[(2-cyclohexylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 40 N-[(5-[(3-[(1R)-1-cyclohexylethyl]amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(3-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[(5-[(3-[(2-propoxyethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(3-[(cyclohexylmethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 45 N-[(5-[(3-[(1-adamantylmethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[(5-[(3-[(3-morpholin-4-ylpropyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 3-methoxy-N-[(5-[(3-[(2-pyridin-2-ylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 3-methoxy-N-[(5-[(3-[(2-piperidin-1-ylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(3-[(2-ethylhexyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 50 N-[(5-[(3-(hexylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 4-chloro-N-[(5-[(3-(heptylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(3-(hexylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 3-methoxy-N-[(5-[(3-(pentylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(3-(butylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide  
 55 4-chloro-N-[(5-[(3-[(2-cyclohexylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(3-[(1-hydroxycyclohexyl)methyl]amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(3-[(1-adamantylmethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide  
 4-chloro-N-[(5-[(3-[(3-morpholin-4-ylpropyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide

4-chloro-N-[[5-({3-[(2-pyridin-2-ylethyl)amino]pyrrolidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({3-[(2-piperidin-1-ylethyl)amino]pyrrolidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({3-[(2-ethylhexyl)amino]pyrrolidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({3-(octylamino)pyrrolidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(pentylamino)methyl]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide

[0056] A further aspect of the present invention consists in the use of the sulfonamide derivatives according to formula I for the preparation of pharmaceutical compositions for the modulation - notably for the down-regulation, e.g. up to the inhibition - of the JNK function or signalling pathway associated disorders, in particular against neuronal disorders and/or against disorders of the immune system as well as said pharmaceutical compositions themselves. Preferred JNK pathways are the JNK1 and/or JNK2 and/or JNK3.

[0057] As pointed out above, the compounds of formula I are suitable to be used as a medicament. Hence, it is herein reported that the compounds falling under the above set out generic formula I are suitable for use in treating disorders of the autoimmune system and neuronal system of mammals, notably of human beings. More specifically, the compounds according to formula I, alone or in the form of a pharmaceutical composition, are useful for the modulation of the JNK pathway, more specifically for treatment or prevention of disorders associated with abnormal expression or activity of JNK, notably of JNK1 and/or JNK2 and/or JNK3. Said modulation usually preferably involves the inhibition of the JNK pathways, notably of the JNK1 and/or JNK2 and/or JNK3. Such an abnormal expression or activity of JNK could be triggered by numerous stimuli (e.g. stress, septic shock, oxidative stress, cytokines) and could lead to out-of-control apoptosis or autoimmune diseases that is frequently involved in the below enumerated disorders and disease states. Hence, the compounds according to formula I could be used for the treatment of disorders by modulating the JNK function or signalling pathways. Said modulation of the JNK function or pathways could involve its activation, but preferably it involves the down-regulation up to inhibition of the JNK pathways, notably of the JNK1 and/or 2 and/or 3. The compounds according to formula I could be employed alone or in combination with further pharmaceutical agents, e.g. with a further JNK modulator.


[0058] Specifically, the compounds pursuant to formula I are useful for the treatment or prevention of immuno- and/or neuronal-related diseases or pathological states in which inhibition of JNK1 and/or 2 and/or 3 plays a critical role such as epilepsy; neurodegenerative diseases including Alzheimer's disease, Huntington's disease, Parkinson's disease; retinal diseases; spinal cord injury; head trauma, autoimmune diseases including multiple sclerosis, inflammatory bowel disease (IBD), rheumatoid arthritis; asthma; septic shock; transplant rejection; cancers including breast, colorectal, pancreatic and cardiovascular diseases including stroke, cerebral ischemia, arterosclerosis, myocardial infarction, myocardial reperfusion injury.

[0059] Quite surprisingly it turned out that the inventively found compounds according to formula I do show a considerable activity as inhibitors of JNK1 and/or 2 and/or 3. According to a preferred embodiment, the compounds according to the invention are essentially inactive in view of 2 further apoptosis modulating enzymes, i.e. p38 and/or ERK2, belonging incidentally to the same family as JNK2 and 3. Hence, the compounds according to the present invention offer the possibility to selectively modulate the JNK pathway, and in particular to treat disorders related to the JNK pathways, while being essentially inefficient with regard to other targets like said p38 and ERK2, so that they could indeed be viewed as selective inhibitors. This is of considerable significance, as these related enzymes are generally involved in different disorders, so that for the treatment of a distinct disorder, it is desired to employ a correspondingly selective medicament.

[0060] Still a further object of the present invention is a process for preparing the novel sulfamide derivatives according to formula I which have been set out above. The sulfonamide derivatives of this invention can be prepared from readily available starting materials using the following general methods and procedures.


[0061] It will be appreciated that where typical or preferred experimental conditions (i.e., reaction temperatures, time, moles of reagents, solvents, etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimisation procedures.

[0062] In a preferred method of synthesis, the sulfonamide derivatives of the invention are prepared by first coupling an amine of formula II:




II

where  $Ar^2$  and  $R^1$  are as defined above, with an acyl chloride of formula III:



III

where Ar<sup>1</sup> is as defined above, to provide an amide of formula IV:



IV

**[0063]** Amines of formula II are either known compounds or can be prepared from known compounds by conventional procedures. Preferred amines as starting materials include thien-2-yl-methylamine, furan-2-yl-methylamine, pyridyl-2-yl-methylamine and the like. The acyl chlorides of formula III are also commercially available or previously described compounds. Preferred acyl chlorides include 4-chlorobenzoyl chloride, 4-fluorobenzoyl chloride, 4-trifluoromethylbenzoyl chloride and the like. If not known, the acid halide can be prepared by reacting the corresponding carboxylic acid with an inorganic acid halide, such as thionyl chloride, phosphorus trichloride or oxalyl chloride under conventional conditions.

**[0064]** Generally, this reaction is performed upon using about 1 to 5 molar equivalents of the inorganic acid halide or oxalyl chloride, either in pure form or in an inert solvent, such as carbon tetrachloride, at temperature in the range of about 0°C to about 80°C for about 1 to about 48 hours. A catalyst, as *N,N*-dimethylformamide, may also be used in this reaction.


**[0065]** When an acyl halide is employed in the coupling reaction, it is typically reacted with amine II in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of example, triethylamine, diisopropylethylamine, *N*-methylmorpholine and the like. Alternatively, an excess of amine II may be used to scavenge the acid generated during the reaction.

**[0066]** Alternatively, the carboxylic acid of compound III can be employed in the coupling reaction. The carboxylic acid of III are usually commercially available reagents or can be prepared by conventional procedures.

**[0067]** The coupling reaction of carboxylic acid of III (i.e. the acyl chloride) is conducted upon using any conventional coupling reagent including, for example, carbodiimides such as dicyclohexylcarbodiimide, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide and other promoting agents, such as *N,N*-carbonyl-diimidazole or PyBOP. This reaction can be conducted with or without the use of well known additives such as *N*-hydroxysuccinimide, 1-hydroxybenzotriazole, etc. which are known to facilitate the coupling of carboxylic acids and amines.

The coupling reaction using either acid halide III or its carboxylic acid is preferably conducted at a temperature of from about 0°C to about 6°C for about 1 to about 24 hours. Typically, the reaction is conducted in an inert aprotic polar solvent such as *N,N*-dimethylformamide, dichloromethane, chloroform, acetonitrile, tetrahydrofuran and the like using about 1 to about 5 molar equivalents of the amine based on the carboxylic acid or its acid halide. Upon completion of the reaction, the carboxamide IV is recovered by conventional methods including precipitation, chromatography, filtration, distillation and the like.

**[0068]** The sulfonyl chlorides of formula V necessary for the preparation of the final products of formula I, notably those being sulfonyl piperidines or -pyrrolidines or -azepans, are prepared using conventional sulfonating methods:



V


**[0069]** A preferred sulfonating reagent for use in this reaction is chlorosulfonic acid. Typically, the sulfonation reaction is performed by treating the carboxamide of formula (IV) with about 5 to about 10 molar equivalent of the sulfonating reagent in an inert solvent, such as dichloromethane, at a temperature ranging from about -70°C to about 50°C. Preferably, the addition of chlorosulfonic acid takes place at -70°C and leads to the formation of the intermediate sulfonic acid. Increasing the temperature to 20°C allows the formation of the sulfonyl chloride of formula V.

**[0070]** According to a further preferred method of preparation notably in case that the above pointed out method

leading to the preliminary synthesis of sulfonyl chloride of formula V is not applicable, the sulfonyl piperidines or pyrrolidines or azepans of this invention are prepared by the following steps:

- Protection of the amine function of compounds of formula II;
- Chlorosulfonylation of the aromatic group;
- Formation of the sulfonamide function;
- Deprotection of the protecting group;
- Acylation of the above generated free amine;

Amines of formula II are protected with a suitable protecting group of an amine moiety to provide intermediate of formula VI wherein P denotes the protecting group.




VI

[0071] Numerous protecting groups P of the amine function as well as their introduction and removal, are well described in T.W. Greene and G.M. Wuts, *Protecting groups in Organic Synthesis*, Third Edition, Wiley, New York, 1998, and references cited therein. Preferred are protecting groups that are acids and bases stable and can be further removed by using metal transition complexes such as palladium complexes, for example the allylcarbamate group (Alloc) or the N,N'-bisallyl group. Another preferred protecting group is the maleimide group which is stable in a all range of experimental conditions.

[0072] The introduction of said groups can be performed by reacting the corresponding bisallylcarbonate anhydride or allylbromide or maleic anhydride in the presence of a base such as triethylamine, diisopropylethylamine, N-methylmorpholine and the like in an aprotic solvent such as N,N-dimethylformamide, dichloromethane, chloroform, acetonitrile, tetrahydrofuran and the like at a temperature ranging from about 0°C to about 80°C.


[0073] Compounds of formula VI are then sulfonated using a conventional very mild sulfonating procedure that allows the obtention of sulfonyl chloride of formula VII.



VII

[0074] Typically, protected amine VI is treated with a base such as n-butyllithium or tert-butyllithium under an inert atmosphere, in a polar aprotic solvent such as tetrahydrofuran, ether or dioxane at a temperature ranging from -70°C to 0°C during a time ranging from 15 minutes to 4 hours. The so formed anion is then treated with SO<sub>2</sub>Cl<sub>2</sub> or most preferably SO<sub>2</sub> by bubbling the gas into the reaction mixture at a temperature ranging from -70°C to 20°C during a time ranging from 5 minutes to 1 hour. The sulfonate obtained is then transformed "in situ" to the sulfonyl chloride of formula VII by contacting with N-chlorosuccinimide at a temperature ranging from 0°C to 70°C.

[0075] The sulfonamide derivatives of formula I are then prepared from the corresponding above mentioned sulfonyl chloride V or VII, by reaction with a cyclic or bicyclic alkyl containing a nitrogen according to the above definition, notably either with a pyrrolidine or azepan or piperidine derivative of the general formula VIII" or VIII' or VIII.



whereby  $(R^6)_n$ ,  $L^1$  and  $L^2$  are as above defined.

**[0076]** The amines of formula VIII or VIII'' or VIII' are either commercially available compounds or compounds that can be prepared by known procedures. Typically, piperidines of type VIII can be prepared upon using conventional methods known by a person skilled in the art.

**[0077]** The sulfonamides of formula I are readily prepared by contacting the sulfonyl chlorides V with an amine of formula VIII in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of examples, triethylamine, diisopropylethylamine, N-methylmorpholine and the like. The reaction is preferably conducted in solvent such as N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone, ethanol, acetonitrile at a temperature from about 0° to about 100°C.

**[0078]** Alternatively, the sulfonamide derivatives of formula I are readily prepared from the corresponding sulfonyl chloride V or VII, by reaction with a piperidine of general formula VIII


**[0079]** Piperidines of formula VIII are either commercially available compounds or compounds that can be prepared by known procedures.

Typically, piperidines of type VIII can be prepared using conventional methods known by one skilled in the art and described by way of examples in *J. Pharm. Sci.* **1972**, 61, 1316; *J. Heterocyclic. Chem.*, **1986**, 23, 73; *Tetrahedron Lett.*, **1996**, 37, 1297, US 5106983, WO/9113872 and WO/9606609.

Preferred methods of obtention of piperidines of formula VIII are the following:

**[0080]** The sulfonamides of formula I are readily prepared by contacting the sulfonyl chloride V with an amine of formula VIII in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of examples, triethylamine, diisopropylethylamine, N-methylmorpholine and the like. The reaction is preferably conducted in solvents such as N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone, ethanol, acetonitrile at a temperature from about 0° to about 100°C.

**[0081]** The sulfonamides of formula XIV are readily prepared by contacting the sulfonyl chloride VII with an amine of formula VIII or IX in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of examples, triethylamine, diisopropylethylamine, N-methylmorpholine and the like. The reaction is preferably conducted in solvents such as N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone, ethanol, acetonitrile at a temperature from about 0° to about 100°C. The use of sulfonyl chloride of type VII leads to amines that have to be deprotected using well known methods by one skilled in the art to afford amine of general formula XIV




XIV

wherein  $R^1$ ,  $Ar^2$ , Y and n are as above defined.

**[0082]** Derivatives of type XIV are then acylated according to described methods for the preparation of amides by condensation of amines with acid chlorides or carboxylic acids in the preferred conditions described above leading to compounds of general formula I

**[0083]** In the particular case of compounds of general formula I where Y represents a piperazine derivative, an alternative method of preparation which has also to be considered as part of this invention, said method of preparation consisting in the condensation of a piperazine derivative of formula XV



XV

with electrophiles L1 which will be chosen depending on the nature of L1 (see the above definition of L1, L2). Procedures and methods to perform these types of condensation are well-known and have been well described on various synthesis of N-substituted piperazine derivatives.

[0084] If the above set out general synthetic methods are not applicable for the obtention of compounds of formula I, suitable methods of preparation known by a person skilled in the art should be used. For example, when Ar<sup>2</sup> is phenyl, one should start from commercially available 4-cyanophenyl sulfonyl chloride and applies conventional methods known by a person skilled in the art to reach sulfonamide derivatives of formula I.

[0085] A final aspect of the present invention is related to the use of the compounds according to formula I for the modulation of the JNK function, or signaling pathways, the use of said compounds for the preparation of pharmaceutical compositions for the modulation of the JNK pathway as well as the formulations containing the active compounds according to formula I. Said modulation of the JNK pathway is viewed as a suitable approach of treatment for various disorders. When employed as pharmaceuticals, the sulfonamide derivatives of the present invention are typically administered in the form of a pharmaceutical composition. Hence, pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable carrier, diluent or excipient therefore are also within the scope of the present invention. A person skilled in the art is aware of a whole variety of such carrier, diluent or excipient compounds suitable to formulate a pharmaceutical composition. Also, the present invention provides compounds for use as a medicament. In particular, the invention provides the compounds of formula I for use as JNK inhibitor, notably JNK1 and/or 2 and/or 3, for the treatment of disorders of the immune as well as the neuronal system of mammals, notably of humans, either alone or in combination with other medicaments.

[0086] The compounds of the invention, together with a conventionally employed adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous use). Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.

[0087] When employed as pharmaceuticals, the sulfonamides derivatives of this invention are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. Generally, the compounds of this invention are administered in a pharmaceutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[0088] The pharmaceutical compositions of these inventions can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. Depending on the intended route of delivery, the compounds are preferably formulated as either injectable or oral compositions. The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders.

[0089] More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampoules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the sulfonamide compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.

[0090] Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch;

a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

**[0091]** Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. As above mentioned, the sulfonamide compound of formula I in such compositions is typically a minor component, frequently ranging between 0.05 to 10% by weight with the remainder being the injectable carrier and the like.

**[0092]** The above described components for orally administered or injectable compositions are merely representative. Further materials as well as processing techniques and the like are set out in Part 8 of *Remington's Pharmaceutical Sciences*, 17<sup>th</sup> Edition, 1985, Marck Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference. The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can also be found in the incorporated materials in *Remington's Pharmaceutical Sciences*.

**[0093]** In the following the present invention shall be illustrated by means of some examples which are not construed to be viewed as limiting the scope of the invention.

### Examples

#### Example 1: Preparation of 3-Methoxy-N-[[5-[[4-[(4-trifluoromethyl-benzyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl]benzamide 1

##### [[[(3-methoxybenzoyl)amino]methyl]thiophene-2-sulfonyl chloride 1a

**[0094]** To a solution of 2-Aminomethylthiophene (10.6ml, 103mmol) and pyridine (9.1ml, 104mmol) in 100ml chloroform was added at 0°C a solution of 3-methoxybenzoylchloride (19.2g, 103mmol) in CH<sub>2</sub>Cl<sub>2</sub>. The reaction was allowed to warm to rt. during 1h and stirred for additional 3h. Water was added while 3-methoxy-N-(thien-2-ylmethyl)benzamide, **1b** (10.1g) precipitated. The solid was filtered off and washed with water. The remaining organic layer was washed with brine, dried over MgSO<sub>4</sub> and evaporated to dryness to afford additional **1b** (15.2g). The overall yield was 25.3 g (99.9%). **1b** was used for the next step without further purification.

**[0095]** Chlorosulfonic acid (5.62ml, 84mmol) was dissolved in 20ml CH<sub>2</sub>Cl<sub>2</sub> and added to a solution of **1b** (11.0g, 42mmol) in 100ml CH<sub>2</sub>Cl<sub>2</sub> under vigorous stirring. A gummy solid was formed and the reaction mixture was stirred for 3h. The reaction was quenched with ice, and ice cold NaHCO<sub>3</sub> solution was added to reach pH8.5. The aqueous layer was washed twice with CH<sub>2</sub>Cl<sub>2</sub>. Tetrabutylammoniumhydroxide (40% in water) (32ml, 50mmol) was added to the aqueous layer, while a solid was formed. The precipitate was extracted into CH<sub>2</sub>Cl<sub>2</sub> and the aqueous layer was washed 3x with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over MgSO<sub>4</sub> and evaporated to dryness to afford a slightly colored foam of Tetrabutylammonium 5-[[[(3-methoxybenzoyl)amino]methyl]thiophene-2-sulfonate **1c** (24g, 97%). NMR spectra indicated pure compound, which was used for the following chlorination step.

**[0096]** To a solution of **1c** (2.0g, 3.4mmol) in 50ml CH<sub>2</sub>Cl<sub>2</sub> was added triphosgene (800mg, 2.7mmol, 2.3eq.), dissolved in 10ml CH<sub>2</sub>Cl<sub>2</sub>. To this reaction mixture DMF (0.1ml, 1.4mmol) was added dropwise during 10', while gas evolution could be observed. The gases were trapped at the outlet of the reaction flask in a 2N NaOH solution. The reaction mixture was stirred for 3h, and the crude was directly filtered through silica gel using EtOAc/hexane 1:2 as eluent. An orange solid could be isolated which was recrystallised from cyclohexane/CH<sub>2</sub>Cl<sub>2</sub>. **1a** (730mg, 60%) was obtained as colorless needles. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.83 (t, J = 1.5 Hz, 1H), 8.35 (t, J = 7.5Hz, 1H), 7.76 (t, J = 4.1 Hz, 1H), 7.70-7.58 (m, 3H), 7.52-7.40 (m, 2H), 7.05 (t, J = 3.8 Hz, 1H).

##### 1-[[5-[[[(3-Methoxybenzoyl)aminomethyl]thien-2-yl)sulfonyl]piperidin-4-ammonium trifluoroacetate 1d

**[0097]** To a solution of 5-[[[(1-(3-Methoxybenzoyl)-amino)-methyl]-thiophene-2-sulfonyl chloride **1a** (8g, 23 mmol) and DIEA (8.7 ml, 50.9 mmol) in 100 ml CH<sub>2</sub>Cl<sub>2</sub> was added a solution of 4-Boc-amino-piperidine (5.5g, 27.7 mmol) in 50ml CH<sub>2</sub>Cl<sub>2</sub>. The reaction mixture was stirred for 4h. Excess of amines were removed by extraction with HCl (1N). The dried organic layer was evaporated to dryness. Recrystallization provided 8.3g (71%) of pure *tert*-butyl 1-[[[(3-Methoxybenzoyl)amino]methyl]thien-2-yl)sulfonyl]piperidin-4-ylcarbamate, **1e**. <sup>1</sup>H NMR showed pure product, which was deprotected according to standard protocols using TFA. The deprotected crude product was precipitated with Diethylether to provide 8.43g (82%) of **1d**: <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 9.29 (t, J = 5.8 Hz, 1H), 7.88 (m, 3H), 7.48-7.36 (m, 4H), 7.17 (d, J = 3.7 Hz, 1H), 7.11 (d, J = 6.8 Hz, 1H), 4.66 (d, J = 5.6 Hz, 2H), 3.79 (s, 3H), 3.61 (d, J = 11.7 Hz, 2H), 3.09 (m, 1H), 2.43 (t, J = 11.1 Hz, 2H), 1.96 (d, J = 11.1 Hz, 2H), 1.54 (dd, J = 11.9, 3.7 Hz, 2H), M/Z APCL: 410.1 (M+1), 408.2 (M-1).

3-Methoxy-N-[(5-[(4-[(4-trifluoromethylbenzyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide 1

[0098] 1d (50mg, 0.1 mmol) was dissolved in 2 ml DCM and neutralized with DIEA (18μl, 0.1mmol) to pH 7. To this solution was added 4-Trifluoromethylbenzaldehyde (18mg, 0.11 mmol), and the reaction was stirred for 30', followed by the addition of acetic acid (6ul, 0.1 mmol) and Sodium triacetoxyborohydride (28mg, 0.14 mmol). The reaction was stirred at r.t. for 4h, diluted with ethylether and quenched with NaOH (1N) to reach pH 9. The organic layer was washed with brine, dried over MgSO<sub>4</sub> and evaporated to dryness. The crude was purified by flash chromatography to obtain 51 mg of pure 1 (91%) as a colorless solid: mp. of HCl salt: 235-236°C, <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 9.29 (t, J = 5.8Hz, 1H), 7.66 (d, J = 8.3 Hz, 2H), 7.65-7.40 (m, 6H), 7.19 (d, J = 3.8 Hz, 1H), 7.15 (dd, J = 7.9, 1.5 Hz, 1H), 4.70 (d, J = 5.6 Hz, 2H), 3.83 (s, 3H), 3.77 (d, b, 2H), 3.41 (d, b, 2H), 2.61-2.40 (m, 3H), 1.93 (m, 2H), 1.42 (m, 2H), M/Z APCI: 568.6 (M+1), 566.6 (M-1).

[0099] Alternatively 1 can be synthesised in a parallel solution phase approach:

[0100] 1d (50mg, 0.1 mmol) was suspended in 2 ml DCE using parallel synthesizer Quest® 210. The suspension was neutralized with DIEA (18μl, 0.1mmol) to pH 7, while 1c is dissolved. To this solution was added 4-Trifluoromethylbenzaldehyde in 100μl DMF (18mg, 0.11 mmol), and the reaction was stirred for 30' under Ar, followed by the addition of acetic acid (6ul, 0.1 mmol) and Sodium triacetoxyborohydride (28mg, 0.14 mmol). The reaction was stirred at r.t. overnight, diluted with DCE and quenched with NaHCO<sub>3</sub> (sat.) to reach pH 9. The organic layer was washed with brine, dried over MgSO<sub>4</sub> and filtered into scintillation vials. 50 mg of polymer bound benzaldehyde and 20 mg of Aminomethyl Merryfield resin were added and shaken overnight. The solution was filtered off, polymers were rinsed twice with solvent and the combined organic layers were evaporated to dryness at medium temperature for 1h using a Savant Speed Vac® Plus vacuum centrifuge.

[0101] The procedure afforded in a parallel array pure 1, as a colourless powder, which was upon treatment with HCl in Diethylether transformed into its HCl salt.

[0102] The following table provides HPLC data and mass spectroscopy data of the mentioned examples. 1,2.

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
2	4-chloro-N-[(5-[(4-[(3-chlorobenzyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.83	99.0	a	600.0	598.0
3	4-chloro-N-[(5-[(4-(4-methoxybenzyl)piperazin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.54	93.3	a	535.0	533.0
4	3-methoxy-N-[(5-[(4-[(4-trifluoromethyl)sulfonyl]benzyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.55	99.9	a	600	598
5	3-methoxy-N-[(5-[(4-[(4-phenoxybenzyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.59	97.9	a	592	590
6	3-methoxy-N-[(5-[(4-[(4-trifluoromethyl)sulfonyl]benzyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.84	97.6	a	632	630
7	3-methoxy-N-[(5-[(4-[(3-methylbenzyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	3.89	95.3	a	514	512

<sup>1</sup> HPLC conditions: C8 Symmetry a- MeCN, 0.09%TFA, 0 to 100% (10min)

<sup>2</sup> Mass spectrum APCI

(continued)

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
8	3-methoxy-N- {[5-( {4-[(4-propylbenzyl)amino] piperidin-1-yl)sulfonyl}thien-2-yl] methyl}benzamide	4.48	99	a	542	540
9	3-methoxy-N- ( {5-[(4-{ [3-(trifluoromethyl)benzyl]amino} piperidin-1-yl)sulfonyl]thien-2-yl] methyl}benzamide	4.27	99.9	a	568	566
10	3-methoxy-N-({5-[(4-{ [4-(trifluoromethoxy)benzyl]amino} piperidin-1-yl)sulfonyl]thien-2-yl] methyl}benzamide	4.53	99.9	a	584	582
11	N- ( {5-[(4-{[4-(difluoromethoxy) benzyl]amino}piperidin-1-yl) sulfonyl]thien-2-yl)methyl}- 3-methoxybenzamide	4.09	98	a	566	564
12	3-methoxy-N-([5-( {4-[(2,3,4,5,6-pentamethylbenzyl) amino]piperidin-1-yl)sulfonyl}thien- 2-yl)methyl}benzamide	4.65	98	a	570	568
13	3-methoxy-N-([5-( {4-[(4-propoxybenzyl)amino] piperidin-1-yl)sulfonyl}thien-2-yl] methyl}benzamide	4.35	98	a	558	556
14	N-([5-[(4-{[4-(butoxybenzyl)amino] piperidin-1-yl)sulfonyl]thien-2-yl] methyl}-3-methoxybenzamide	4.65	99.9	a	572	570
15	3-methoxy-N-([5-( {4-[(4-methoxybenzyl)amino] piperidin-1-yl)sulfonyl}thien-2-yl] methyl}benzamide	3.73	98	a	530	528
16	3-methoxy-N-([5-[(4-[(pyridin- 4-ylmethyl)amino]piperidin-1-yl] sulfonyl]thien-2-yl)methyl} benzamide	2.72	99.9	a	501	499
17	3-methoxy-N-([5-[(4-[(pyridin- 2-ylmethyl)amino]piperidin-1-yl] sulfonyl]thien-2-yl)methyl]- benzamide	3.27	99.2	a	501	499
18	3-methoxy-N-([5-[(4-[(pyridin- 3-ylmethyl)amino]piperidin-1-yl] sulfonyl]thien-2-yl)methyl] benzamide	2.79	99.9	a	501	499
19	3-methoxy-N-([5-[(4-[(quinolin- 4-ylmethyl)amino]piperidin-1-yl] sulfonyl]thien-2-yl)methyl] benzamide	3.02	99.9	a	551	549

(continued)

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
20	N-[[5-[(4-[(4-tert-butylbenzyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	4.64	99.7	a	556	554
21	N-[[5-[(4-[(3-ethoxybenzyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	4.01	97.3	a	544	542

**Example 22: Preparation of 4-chloro-N-[(5-[(4-(hexylamino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide****4-Chloro-N-thiophen-2-ylmethyl-benzamide 22a**

**[0103]** A solution of 4-chlorobenzoyl chloride (0.114 mol) in 50 ml dry  $\text{CH}_2\text{Cl}_2$  was added over 30 min to a stirred solution of 2-aminomethyl-thiophene (0.137 mol) and  $\text{IPr}_2\text{NEt}$  (0.25 mol) in  $\text{CH}_2\text{Cl}_2$  (200 ml) at  $0^\circ\text{C}$ . A white solid was formed and the reaction was allowed to warm to room temperature over 1 h. The mixture was diluted with 200 ml of  $\text{CH}_2\text{Cl}_2$ , washed twice with HCl aq. (0.1N) and dried over  $\text{MgSO}_4$ . Evaporation of the solvents afforded 28 g (98%) of the title benzamide as a white solid: m.p.  $153\text{--}54^\circ\text{C}$ ,  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.9 (d,  $J = 8.67$  Hz, 2H), 7.58 (d,  $J = 8.67$  Hz, 2H), 7.44 (dd,  $J = 3.77, 1.13$  Hz, 1H), 7.22 (d,  $J = 5.27$  Hz, 1H), 7.16 (dd,  $J = 3.39, 5.27$  Hz, 1H), 6.62 (br d, 1H), 4.98 (d,  $J = 5.65$  Hz, 2H).

**5-[(1-(4-Chloro-phenyl)-methanoyl)-amino]-methyl)-thiophene-2-sulfonyl chloride 22b**

**[0104]** Chlorosulfonic acid (20.1 ml, 198 mmol) in  $\text{CH}_2\text{Cl}_2$  (80 ml) was added dropwise to a solution of **22a** (10 g, 40 mmol) in  $\text{CH}_2\text{Cl}_2$  (500 ml) at  $-80^\circ\text{C}$ . The mixture was allowed to reach room temperature in 5h.. The reaction mixture was poured on ice and quickly extracted with  $\text{CH}_2\text{Cl}_2$ . The organic layer was dried over  $\text{MgSO}_4$  and the solvent was evaporated to dryness which afforded 8.8 g (63%) of desired sulfonyl chloride **22b**; mp  $133\text{--}35^\circ\text{C}$ ,  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  9.21 (t,  $J = 6.4$  Hz, 1H), 7.87 (d,  $J = 8.67$  Hz, 2H), 7.53 (d,  $J = 8.67$  Hz, 2H), 6.91 (d,  $J = 3.39$  Hz, 1H), 6.77 (d,  $J = 3.39$  Hz, 1H), 4.53 (d,  $J = 3.77$  Hz, 2H).

**4-Chloro-N-[(5-[(4-oxopiperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide 22c**

**[0105]** A solution of 5-[(1-(4-Chloro-phenyl)-methanoyl)-amino]-methyl)-thiophene-2-sulfonyl chloride **1b** (5.0g, 14mmol) in 100ml chloroform and a solution of 4-piperidinone hydrochloride monohydrate (4.3g, 28mmol) in 21ml of NaOH (2N) were stirred vigorously for 15h. The reaction was quenched with HCl (2N) and the organic layer was extracted twice with HCl (2N) and twice with brine. The dried organic phase affords after evaporation of chloroform 5.8g (99.5%) of **22c** as a colourless solid:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.67 (d,  $J = 8.7$  Hz, 2H), 7.42-7.38 (m, 3H), 6.99 (d,  $J = 3.8$  Hz, 1H), 6.53 (t,  $J = 5.3$  Hz, 1H), 4.74 (d,  $J = 6.0$  Hz, 2H), 3.37 (d,  $J = 6.2$  Hz, 4H), 2.50 (d,  $J = 6.2$  Hz, 4H).

**4-Chloro-N-[(5-[(4-(hexylamino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide 22**

**[0106]** A mixture of N-sulfonyl piperidone **22c** (3.01 g, 7.28 mmol), n-hexylamine (1.06 ml, 8.01 mmol), freshly powdered  $\text{NaBH}(\text{OAc})_3$  (3.1 g, 14.6 mmol), anhydrous 1,2-dichloroethane (150 ml), and THF (100 ml) was stirred for 80 min at  $23^\circ\text{C}$ . The mixture was concentrated on a rotary evaporator ( $T_{\text{bath}} = 57^\circ\text{C}$ ), dissolved in EtOAc (500 ml), washed (brine: $\text{K}_2\text{CO}_3$  sat, 4:1; 250 ml) and evaporated to give 4.1 g of crude material. The residue was dissolved in 50 ml hot acetone, adsorbed on silica gel, evaporated, loaded on a chromatography column (silica gel, diameter = 5.5 cm), and eluted ( $\text{MeOH}:\text{CH}_2\text{Cl}_2$  7:150). The chromatography was repeated to give 2.95 g (81%) of the title secondary amine as a white solid:  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ) 9.37 (t,  $J = 5.8$  Hz, 1H), 7.90 (dt,  $J = 8.7, 2.2$  Hz, 2H), 7.51 (dt,  $J = 8.5, 2.2$  Hz, 2H), 7.16 (d,  $J = 3.8$  Hz, 1H), 4.65 (d,  $J = 5.8$  Hz, 2H), 3.39 (dm,  $J = 11.9$  Hz, 2H), 3.60-3.00 (br. s, 1H), 2.49 (ddd,  $J = 11.5, 9.8, 1.7$  Hz, 2H), 2.43 (t,  $J = 6.9$  Hz, 2H), 2.44-2.38 (buried m, 1H), 1.82 (dm,  $J = 10.0$  Hz, 2H), 1.38-1.14 (m, 10H), 0.83 (t,  $J = 6.7$  Hz).  $^{13}\text{C}$  NMR ( $\text{DMSO}-d_6$ ) 165.33 (C=O), 150.46 (thiophene, C2), 136.41 (chlorobenzamide, C1), 133.86 (thiophene, C5), 132.42 (thiophene, C3), 132.37 (chlorobenzamide, C4), 129.22 (chlorobenzamide, C2 & C6), 128.52 (chlorobenzamide, C3 & C5), 126.27 (thiophene, C4), 52.53 (piperidine, C4), 46.07 (hexyl), 44.41 (piperidine, C2 & C6), 38.09 (thienyl- $\text{CH}_2$ ), 31.21 (piperidine, C3 & C5), 30.66 (hexyl), 29.49 (hexyl), 26.48 (hexyl), 22.06 (hexyl), 13.91

(hexyl). ). M/Z APCI : 498 (M+1), 496 (M-1). Anal. HPLC: R.t = 5.00 min (method a).  $C_{23}H_{32}ClN_3O_3S_2$  Calc.: C: 55.46%, H: 6.48%, N: 8.44%. Found: C: 54.19%, H: 6.52%, N: 8.22%.

**[0107]** Alternatively **22** can be synthesised in a parallel solution phase approach:

**22c** (20mg, 0.05 mmol) was dissolved in 2 ml THF using parallel synthesizer Quest® 210. To this solution was added N-hexylamine in DCE (5.6mg, 0.06 mmol), and the reaction was stirred for 30' under Ar, followed by the addition of acetic acid (6ul, 0.1 mmol) and Sodium triacetoxyborohydride (28mg, 0.14 mmol). The reaction was stirred at r.t. for 4h, diluted with DCE and quenched with  $NaHCO_3$  (sat.) to reach pH 8.5. The organic layer was washed with brine, dried over  $MgSO_4$  and filtered into scintillation vials. To each vial was added MP-TsOH (3eq.) and shaken overnight. The solution was filtered off and the polymer was rinsed extensively with DCE. To the polymer was then added 3 times 1ml  $NH_3$  in EtOH and shaken each for 10min. The polymer was washed and the combined ethanolic solution was evaporated to dryness at medium temperature for 1h using a Savant Speed Vac® Plus vacuum centrifuge.

The procedure afforded in a parallel array pure **22**, as a colourless powder, which was upon treatment with HCl in Diethylether transformed into its HCl salt.

The following compounds were prepared on a parallel fashion according to the examples described above :

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
<b>23</b>	4-chloro-N-[(5-[(4-(heptylamino) piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	5.27	100	a	515	513
<b>24</b>	4-chloro-N-[(5-[(4-(pentylamino) piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.72	95.5	a	514	512
<b>25</b>	4-chloro-N-[(5-[(4-(butylamino) piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.41	100	a	483	481
<b>26</b>	4-chloro-N-[(5-[(4-(dodecylamino) piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	6.59	100	a	494	492
<b>27</b>	4-chloro-N-[(5-[(4-[(2-cyclohexylethyl)amino] piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	5.25	95	a	594	592
<b>28</b>	4-chloro-N-[(5-[(4-[(cyclohexylmethyl)amino] piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.87	100	a	588	586
<b>29</b>	4-chloro-N-[(5-[(4-[(1R)-1-cyclohexylethyl]amino] piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	5.03	100	a	589	587
<b>30</b>	N-[(5-[(4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino] piperidin-1-yl)sulfonyl]thien-2-yl)methyl]4-chlorobenzamide	4.64	96.4	a	495	493
<b>31</b>	4-chloro-N-[(5-[(4-[(2-propoxyethyl)amino] piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.53	100	a	512	510
<b>32</b>	N-[(5-[(4-[(1-adamantylmethyl)amino] piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide	5.53	100	a	582	580

(continued)

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
33	4-chloro-N-{{5-({4-((2-pyridin-2-ylethyl)amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	3.75	99.4	a	528	526
34	4-chloro-N-{{5-({4-((2-piperidin-1-ylethyl)amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	3.76	98.5	a	568	566
35	4-chloro-N-{{5-({4-((2-ethylhexyl)amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	5.41	99.3	a	526	524
36	4-chloro-N-{{5-({4-((octylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	5.57	100	a	528	526
37	N-{{5-({4-((heptylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-3-methoxy-benzamide	5.03	92.0	a	530	528
38	3-methoxy-N-{{5-({4-((octylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	5.30	79.5	a	528	526
39	3-methoxy-N-{{5-({4-((pentylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	4.37	93.0	a	484	482
40	N-{{5-({4-((butylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-3-methoxybenzamide	4.07	93.3	a	454	0
41	N-{{5-({4-((dodecylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-3-methoxybenzamide	6.39	86.7	a	536	534
42	3-methoxy-N-{{5-({4-((nonylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	4.63	100	a	536	534
43	3-methoxy-N-{{5-({4-((decylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	4.90	100	a	550	548
44	N-{{5-({4-((ethylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-3-methoxybenzamide	2.59	100	a	438	436
45	N-{{5-({4-((2-cyclohexylethyl)amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-3-methoxybenzamide	4.91	92	a	550	548
46	N-{{5-({4-((1R)-1-cyclohexylethyl)amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-3-methoxybenzamide	4.67	93.0	a	438	436

(continued)

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
47	N-[[5-({4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide	4.29	95.4	a	566	564
48	3-methoxy-N- { [5-( {4-[(2-propoxyethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	4.16	91.3	a	589	587
49	N-[[5-({4-[(1-adamantylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide	5.04	100	a	589	587
50	N-[[5-({4-[(3,3-diethoxypropyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide	3.87	89.0	a	658	656
51	3-methoxy-N-[[5-({4-[(3-morpholin-4-ylpropyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide	3.30	91.2	a	554	552
52	3-methoxy-N- { [5-( {4-[(2-pyridin-2-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	3.37	94.0	a	616	614
53	3-methoxy-N- { [5-( {4-[(2-piperidin-1-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	3.40	89.7	a	602	600
54	N-[[5-({4-[(2-ethylhexyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide	5.10	98.4	a	590	588
55	N-[[5-({4-[(hexylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide	4.65	92.9	a	520	518
56	3-methoxy-N-[(5-[[4-( {2-[3-(trifluoromethyl)phenyl]ethyl}amino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide	4.07	100			
57	3-methoxy-N-({5-[(4-{ [2-(4-methylphenyl)ethyl]amino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	3.73	100	a	528	526
58	3-methoxy-N-({5-[(4-{ [4-(trifluoromethyl)benzyl]amino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	3.75	100	a	568	566
59	3-methoxy-N-({5-[(4-{ [(1S,2R)-2-phenylcyclopropyl]amino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide	3.62	100	a	526	524

(continued)

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
60	3-methoxy-N- { [5-( {4-[(1-naphthylmethyl)amino] piperidin-1-yl)sulfonyl}thien-2-yl] methyl}benzamide	3.66	94.9	a	550	548
61	3-methoxy-N-[[5-( {4-[(2-phenylpropyl)amino] piperidin-1-yl)sulfonyl}thien-2-yl] methyl}benzamide	3.56	100	a	528	526
62	N-({5-[(4-[(2-(4-hydroxyphenyl) ethyl)amino]piperidin-1-yl)sulfonyl] thien-2-yl)methyl}- 3-methoxybenzamide	3.02	100	a	530	528
63	3-methoxy-N-[[5-( {4-[(3-phenylpropyl)amino] piperidin-1-yl)sulfonyl}thien-2-yl] methyl}benzamide	3.68	100	a	528	526
64	N- { [5-[(4-[(2,3-dihydroxypropyl) amino]piperidin-1-yl)sulfonyl]thien- 2-yl)methyl]-3-methoxybenzamide	2.42	100	a	484	482
65	N-[[5-[(4-[(2-hydroxyethyl)amino] piperidin-1-yl)sulfonyl]thien-2-yl] methyl]-3-methoxybenzamide	2.47	58.6	a	454	0
66	N-[[5-[(4-[(2-[1,1'-biphenyl]- 4-ylethyl)amino]piperidin-1-yl] sulfonyl]thien-2-yl)methyl]- 3-methoxybenzamide	4.48	96.7	a	590	588
67	N-[[5-[(4-[(1,1'-biphenyl]- 3-ylmethyl)amino]piperidin-1-yl] sulfonyl]thien-2-yl)methyl]- 3-methoxybenzamide	4.24	92.6	a	576	574
68	3-methoxy-N-[[5-[(4-[(2-thien- 2-ylethyl)amino]piperidin-1-yl] sulfonyl]thien-2-yl)methyl] benzamide	3.78	92.1	a	520	518

**Example 69:** 5-[[[(3-methoxybenzoyl)amino]methyl]-2-[(4-(octylamino)piperidin-1-yl)sulfonyl]thiophene-3-carboxylic acid **69**

**Diallyl-thiophen-2-ylmethylamine 69a**

**[0108]** A solution of 2-aminomethyl-thiophene (51.4 g, 956 mmol) and *i*-Pr<sub>2</sub>NEt (140 g, 1081 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 l) was placed in a 3-l flask equipped with a condenser and an efficient magnetic agitation. Allyl bromide (115.7 g, 454 mmol) was added, whereupon the moderately exothermic reaction spontaneously reached the reflux temperature after 2 h.

**[0109]** The mixture was stirred overnight (16 h), washed (NaHCO<sub>3</sub> sat.; brine), dried (MgSO<sub>4</sub>), and concentrated. The resulting oil was filtered over silica gel (EtOAc:hexane 1:4). The filtrate was concentrated and the filtration was repeated to afford 70.3 g (80%) of the title diallylamine as a brown-yellow oil, clean by NMR: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.25 (br. d, *J* = 5.9 Hz, 1H), 6.98 (br. dd, *J* = 5.1, 2.8 Hz, 1H), 6.94-6.92 (m, 1H), 5.99-5.86 (m, 2H), 5.29-5.18 (m, 4H), 3.85 (s, 2H), 3.16 (dd, *J* = 6.3, 0.9 Hz, 4H).

5-Diallylaminomethyl-thiophene-2-sulfonyl chloride 69b

[0110] A solution of the allyl-protected thiophene 69a (6.2 g, 32.1 mmol) in Et<sub>2</sub>O was cooled to -70°C by means of an acetone/dry ice bath. A solution of *t*-BuLi in pentane (21.38 ml, 1.5M, 32.1 mmol) was added over 2 min whereupon the internal temperature momentarily rose to -50°C and the mixture turned orange. After 10 min., SO<sub>2</sub> was bubbled for 2 min, which led to the immediate formation of a thick precipitate. The reaction was allowed to reach 0°C, and a suspension of NCS (4.63 g, 32.1 mmol) in THF (20 ml) was added, whereupon the slurry turned purple. After 45 min at r.t., the mixture was filtered over SiO<sub>2</sub>, eluting with EtOAc. Evaporation, dilution with EtOAc:hexane 1:5 and filtration over SiO<sub>2</sub> gave 5.0 g (53%) of the title sulfonyl chloride 69b as a pale brown oil which was used without further purification.

*N,N*-Diallyl-*N*-{[5-(1,4-dioxo-8-azaspiro[4.5]dec-8-ylsulfonyl)thien-2-yl]methyl} amine 69c

[0111] Procedure A (from the isolated sulfonyl chloride 69b). A solution of 69b (5.84 g, 20 mmol) in CHCl<sub>3</sub> was cooled to 0°C, and treated with 1,4-dioxo-8-azaspiro[4.5]decane (2.8 ml, 22 mmol) and Et<sub>3</sub>N (4.2 ml, 30 mmol), and warmed to 23°C for 10 min. Dilution with EtOAc (100 ml), standard work-up (NaHCO<sub>3</sub> sat.; brine; MgSO<sub>4</sub>) and chromatography (EtOAc:cyclohexane 1:2) gave 7.57 g (95%) of the title sulfonamide as a colourless oil.

[0112] Procedure B (from 69a, without isolation of the sulfonyl chloride 69b). A solution of the allyl-protected thiophene 1a (29.1 g, 150 mmol) in Et<sub>2</sub>O (440 g, 617 ml) was placed in a 1-l three-necked flask (thermometer; argon; septum or SO<sub>2</sub> inlet) and cooled to -74°C by means of an acetone/dry ice bath. A solution of *t*-BuLi in pentane (100 ml, 1.5M, 150 mmol) was added over 5 min whereupon the internal temperature momentarily rose to -64°C and the mixture turned pink. After 20 min., SO<sub>2</sub> (20 g, 312 mmol) was bubbled over 15 min. The SO<sub>2</sub> consumption was best monitored by placing the SO<sub>2</sub> bottle on a scale during the reaction. The reaction mixture, which had turned to a thick, white wax was allowed to warm to room temperature over 2h. A suspension of NCS (30 g, 226 mmol) was added, and stirring was continued overnight, whereupon the slurry turned purple. The mixture was filtered (fritted glass), and the precipitate was carefully washed with CH<sub>2</sub>Cl<sub>2</sub> (2 x 300 ml). The combined organic layers were cooled to 0°C under Ar, and treated with a solution of 1,4-dioxo-8-azaspiro[4.5]decane (27.8 g, 194 mmol) and triethylamine (19.7 g, 194 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (200 ml). After 1 h, the mixture was washed (NaHCO<sub>3</sub> sat.; brine), dried (MgSO<sub>4</sub>), and concentrated to afford 53 g (83%) of the title sulfonamide as yellow oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.36 (d, *J* = 3.8 Hz, 1H), 6.90 (br. d, *J* = 3.4 Hz, 1H), 5.92-5.79 (m, 2H), 5.33-5.16 (m, 4H), 3.93 (s, 4H), 3.78 (s, 2H), 3.21 (t, 5.7 Hz, 4H), 3.13 (d, 6.2 Hz, 4H), 1.81 (t, 5.7 Hz, 4H).

Ethyl 5-[(diallylamino)methyl]-2-(1,4-dioxo-8-azaspiro[4.5]dec-8-ylsulfonyl)thiophene-3-carboxylate 69d

[0113] A solution of the sulfonamide 69c (3.36 g, 8.43 mmol) in THF (120 ml) was cooled to -78°C and treated with *t*-BuLi (7.0 ml, 1.5M in hexane, 10.5 ml). After 5 min, the mixture was cannulated into a cooled (-100°C; acetone/liquid N<sub>2</sub>) solution of ethyl chloroformate (6.45 ml, 67.5 mmol) in THF (60 ml). The reaction mixture was allowed to warm to -30°C over 2h, and then to 23°C overnight. The mixture was concentrated on a rotary evaporator and diluted with EtOAc (250 ml). Standard work-up (H<sub>2</sub>O; brine; MgSO<sub>4</sub>) and two chromatographies (EtOAc:cyclohexane 1:4) afforded 1.48 (37%) of the title ethyl ester: <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 7.36 (d, 1H), 5.98-5.82 (m, 2H), 5.32-5.17 (m, 4H), 4.33 (q, *J* = 7.1 Hz, 2H), 3.92 (s, 4H), 3.85 (s, 2H), 3.32 (dd, *J* = 6.0, 5.0 Hz, 4H), 3.17 (d, *J* = 6.0 Hz, 4H), 1.74 dd, *J* = 6.0, 5.0 Hz, 4H), 1.33 (t, *J* = 7.2 Hz, 3H).

Ethyl 2-(1,4-dioxo-8-azaspiro[4.5]dec-8-ylsulfonyl)-5-[(3-methoxybenzoyl)amino]methylthiophene-3-carboxylate 69e

[0114] A solution of the ethyl ester 69d (1.47 g, 3.12 mmol) and NDMBA (1.07 g, 6.87 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 ml) was degassed by bubbling argon and sonicating. Then, Pd(PPh<sub>3</sub>)<sub>4</sub> (216 mg, 0.187 mmol) was added and the mixture was stirred at 23°C. After 2h, the mixture was cooled to -50°C, treated with Et<sub>3</sub>N (525 ul, 3.76 mmol) and 3-(methoxy)benzoyl chloride (300ul, 2.13 mmol), and warmed to r.t. over 30 min. Dilution with EtOAc, standard work-up (H<sub>2</sub>O; NaHCO<sub>3</sub> sat.; brine; MgSO<sub>4</sub>) and chromatography (EtOAc:cyclohexane 1:1) afforded 1.0 g (61%) of the title 3-methoxybenzamide: <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) 9.29 (t, *J* = 5.8 Hz, 1H), 7.49-7.34 (m, 4H), 7.12 (ddd, *J* = 7.9, 2.6, 1.0 Hz, 1H), 4.66 (d, *J* = 5.7 Hz, 2H), 4.27 (q, *J* = 7.2 Hz, 2H), 3.84 (s, 4H), 3.80 (s, 3H), 3.24 (dd, *J* = 6.0, 5.0 Hz, 4H), 1.67 (dd, *J* = 6.0, 5.0 Hz, 4H), 1.26 (t, *J* = 7.0 Hz, 3H). M/Z APCI: 525 (M + 1), 523 (M - 1).

Ethyl 5-[(3-methoxybenzoyl)amino]methyl-2-[(4-oxopiperidin-1-yl)sulfonyl]thiophene-3-carboxylate 69f

[0115] A solution of the spiroketal 69e (500 mg, 0.953 mmol) in acetone (5 ml) was treated with HCl 1N (2.5 ml) for

18 h at 48°C. Dilution with EtOAc and standard work-up (H<sub>2</sub>O; NaHCO<sub>3</sub> sat.; brine; MgSO<sub>4</sub>) gave 425 mg of a 9:1 mixture of the desired title ketone (83%) and of unreacted starting material (9%) (single spot by TLC). <sup>1</sup>H NMR (CDCl<sub>3</sub>) 7.37-7.35 (m, 1H), 7.33-7.29 (m, 3H), 7.05 (ddd, *J* = 7.7, 2.6, 1.7 Hz, 1H), 6.81 (t, *J* = 5.8 Hz, 1H), 4.74 (d, *J* = 6.1 Hz, 2H), 4.31 (q, *J* = 7.1 Hz, 2H), 3.83 (s, 3H), 3.70 (t, *J* = 6.1 Hz, 4H), 2.52 (t, *J* = 6.2 Hz, 4H), 1.34 (t, *J* = 7.1 Hz, 3H). M/Z APCI: 481 (M + 1), 479 (M-1).

Ethyl 5-[[[(3-methoxybenzoyl)amino]methyl]-2-[[4-(octylamino)piperidin-1-yl]sulfonyl]thiophene-3-carboxylate 69g

[0116] A suspension of the crude ketone **69f** (425 mg, 0.803 mmol), octylamine (287 mg, 1.27 mmol), and 3 Å powdered MS (3 g) in dry tetrachloroethylene (15 ml) was heated to reflux for 17h under strictly anhydrous conditions. The mixture was cooled to 23°C, and finely powdered NaBH(OAc)<sub>3</sub> (1.2 g) was added. The stirring was continued for 2.5 d. Dilution with EtOAc, standard work-up (NaHCO<sub>3</sub> sat.; brine; MgSO<sub>4</sub>) and chromatography (EtOAc:cyclohexane 1:1.5 → 2:1) afforded 167 mg (35%) of a mixture of the starting ketone **69f** and spiroketal **69e**, and 216 mg (39%) of the title anilinopiperidine.

5-[[[(3-methoxybenzoyl)amino]methyl]-2-[[4-(octylamino)piperidin-1-yl]sulfonyl]thiophene-3-carboxylic acid 69

[0117] A solution of the ethyl ester **69g** (40 mg, 0.058 mmol) in MeOH (4 ml) was treated with NaOH 2M (0.8 ml) for 2 h at 45°C. The mixture was diluted with EtOAc, washed (NH<sub>4</sub>Cl aq.; H<sub>2</sub>O; brine), dried (MgSO<sub>4</sub>), concentrated to 2 ml, and filtered over celite, eluting with EtOAc. Evaporation gave 40 mg (96%) of the title acid. M/Z APCI: 662 (M+1), 660 (M-1), 616 (M-CO<sub>2</sub>-1). Anal. HPLC: R.t = 6.55 min (method a).

Example 70 :N-[[5-[[4-(heptylamino)azepan-1-yl]sulfonyl]thien-2-yl)methyl]-3-methoxy-benzamide 70

[0118] The corresponding 3-Methoxy-*N*-[[5-[[4-(oxoazepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide **70a**, was prepared according to example 22 and could be isolated as colourless powder in quantitative yield (693 mg). M/Z APCI: 423.5 (M+1), 421 (M-1).

Anal. HPLC: R.t = 4.97 min (method a).

**70** was prepared according to the protocol example 22 and was isolated as colourless solid in 47% yield (12mg). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 9.25 (t, *J* = 5.8 Hz, 1H), 7.46-7.35 (m, 4H), 7.10 (m, 2H), 4.65 (d, *J* = 6.0 Hz, 2H), 3.79 (s, 3H), 3.29-3.20 (m, 2H), 3.12 (m, 2H), 2.58 (m, 1H), 2.49 (m, 2H), 1.75 (m, 2H), 1.44-1.22 (m, 14H), 0.85 (t, *J* = 6.9 Hz, 3H). M/Z APCI: 522.5 (M+1), 520 (M-1).

[0119] Alternatively **70** can be synthesised in a parallel solution phase approach according to the synthesis described for **22**.

The following compounds were prepared on a parallel fashion according to the examples described above

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
<b>71</b>	3-methoxy-N-[[5-[[4-(octylamino)azepan-1-yl]sulfonyl]thien-2-yl)methyl]benzamide	5.38	100.0	a	536	534
<b>72</b>	3-methoxy-N-[[5-[[4-(pentylamino)azepan-1-yl]sulfonyl]thien-2-yl)methyl]benzamide	4.45	100.0	a	494	492
<b>73</b>	N-[[5-[[4-(butylamino)azepan-1-yl]sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	4.14	100.0	a	480	478
<b>74</b>	N-[[5-[[4-(dodecylamino)azepan-1-yl]sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	6.44	100.0	a	592	590
<b>75</b>	N-[[5-[[4-[[2-(cyclohexylethyl)amino]azepan-1-yl]sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	5.01	95.4	a	534	532

(continued)

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
76	N-({5-[(4-[(1R)-1-cyclohexylethyl]amino)azepan-1-yl]sulfonyl}thien-2-yl)methyl)-3-methoxybenzamide	4.76	100.0	a	534	532
77	N-({5-[(4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]azepan-1-yl]sulfonyl}thien-2-yl)methyl)-3-methoxybenzamide	4.83	100.0	a	518	516
78	3-methoxy-N-({5-[(4-[(2-propoxyethyl)amino]azepan-1-yl]sulfonyl}thien-2-yl)methyl)benzamide	4.22	100.0	a	510	508
79	N-({5-[(4-[(cyclohexylmethyl)amino]azepan-1-yl]sulfonyl}thien-2-yl)methyl)-3-methoxybenzamide	4.62	100.0	a	520	518
80	N-({5-[(4-[(1-adamantylmethyl)amino]azepan-1-yl]sulfonyl}thien-2-yl)methyl)-3-methoxybenzamide	5.11	100.0	a	572	570
81	3-methoxy-N-({5-[(4-[(3-morpholin-4-ylpropyl)amino]azepan-1-yl]sulfonyl}thien-2-yl)methyl)benzamide	3.55	100.0	a	551	549
82	3-methoxy-N-({5-[(4-[(2-pyridin-2-ylethyl)amino]azepan-1-yl]sulfonyl}thien-2-yl)methyl)benzamide	3.38	100.0	a	529	527
83	3-methoxy-N-({5-[(4-[(2-piperidin-1-ylethyl)amino]azepan-1-yl]sulfonyl}thien-2-yl)methyl)benzamide	3.44	100.0	a	535	533
84	N-({5-[(4-[(2-ethylhexyl)amino]azepan-1-yl]sulfonyl}thien-2-yl)methyl)-3-methoxybenzamide	5.20	100.0	a	536	534
85	N-({5-[(4-[(3-(1H-imidazol-1-yl)propyl)amino]azepan-1-yl]sulfonyl}thien-2-yl)methyl)-3-methoxybenzamide	3.32	100.0	a	532	530
86	4-chloro-N-({5-[(4-(heptylamino)azepan-1-yl]sulfonyl}thien-2-yl)methyl)benzamide	5.37	100.0	a	526	524
87	4-chloro-N-({5-[(4-(octylamino)azepan-1-yl]sulfonyl}thien-2-yl)methyl)benzamide	5.63	100.0	a	540	538
88	4-chloro-N-({5-[(4-(pentylamino)azepan-1-yl]sulfonyl}thien-2-yl)methyl)benzamide	4.78	100.0	a	498	496

(continued)

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
89	N-[(5-[(4-(butylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide	4.49	10'0	a	484	482
90	4-chloro-N-[(5-[(4-(dodecylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	6.66	100.0	a	596	594
91	4-chloro-N-[(5-[(4-[(2-cyclohexylethyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	5.28	95.2	a	538	0
92	N-[(5-[(4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide	4.71	100.0	a	522	520
93	4-chloro-N-[(5-[(4-[(2-propoxyethyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.57	100.0	a	514	512
94	4-chloro-N-[(5-[(4-[(2-ethylhexyl)amino]azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	5.44	100.0	a	540	538
95	4-chloro-N-[(5-[(4-(hexylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	5.04	100.0	a	512	510
96	3-methoxy-N-[(5-[(4-(hexylamino)azepan-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.77	100.0	a		

**Example 97:** Preparation of 4-Chloro-N-[(5-[(4-[hexyl(pyridin-2-ylmethyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide 97

[0120] A solution of AS601730 (19.6 mg, 0.039 mmol) and pyridine 2-carbaldehyde (20  $\mu$ l, 0.210 mmol) in THF (2.5 ml) was treated with  $\text{NaBH}(\text{OAc})_3$  (90 mg, 0.425 mmol) under argon at reflux over 16h. The mixture was cooled to r.t. and the excess aldehyde was removed with aminomethyl polystyrene resin (160 mg, 0.308 mmol, pre-suspended in 4 ml  $\text{CH}_2\text{Cl}_2$ ) for 10 min at 23°C. Dilution with  $\text{CH}_2\text{Cl}_2$  (10 ml), filtration over cotton-wool, and standard work-up ( $\text{H}_2\text{O}$ ; brine;  $\text{MgSO}_4$ ) afforded 17.8 mg (77%) of the title tertiary amine as a pale yellow oil.  $M/Z$  APCI: 589 (M+1), 587 (M-1). Anal. HPLC: R.t = 5.00 min (method a, 96% optical purity (254 nm)).

[0121] In this protocol, pyridine-2-carbaldehyde could be replaced with other aldehydes, which include (but are not limited to): pyridine-3-carbaldehyde, pyridine-4-carbaldehyde, benzaldehyde, cyclohexanecarbaldehyde.

[0122] The following table provides HPLC data and mass spectroscopy data of the mentioned examples. <sup>3,4</sup>

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
98	4-chloro-N-[(5-[(4-[(cyclohexylmethyl)(hexyl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	5.87	64.3	a	594	592

<sup>3</sup> HPLC conditions: C8 Symmetry a- MeCN, 0.09%TFA, 0 to 100% (10min)

<sup>4</sup> Mass spectrum APCI

(continued)

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
99	N-[[5-((4-[benzyl(hexyl)amio]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide	5.53	87.0	a	588	586
100	4-chloro-N-[[5-((4-[hexyl(pyridin-3-ylmethyl)amino]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide	4.56	77.5	a	589	587
101	4-chloro-N-[[5-((4-[hexyl(pyridin-4-ylmethyl)amino]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide	4.11	91.3	a	589	587
102	N-[[5-((4-[(5-bromo-2-furyl)methyl](hexyl)amino]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide	5.29	90.7			
103	N-[[5-((4-[butyl(hexyl)amino]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide	5.18	94.4	a	554	552
104	4-chloro-N-[[5-((4-[hexyl(3-phenylpropyl)amino]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide	5.61	94.3	a	616	614
105	4-chloro-N-[[5-((4-[hexyl(2-phenylethyl)amino]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide	5.47	94.4	a	602	600
106	4-chloro-N-[[5-((4-[hexyl(methyl)amino]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide	5.04	96.2	a	512	510

**Example 107: Preparation of 4-chloro-N-[[5-((3-(pentylamino)pyrrolidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide 107****4-chloro-N-[[5-((3*R*)-3-hydroxypyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide, 107a**

**[0123]** To a suspension of R-3-pyrrolidinol hydrochloride (530mg, 4.29 mmol) and DIEA (0.75ml, 14.3mmol) in CH<sub>2</sub>Cl<sub>2</sub>/DMF 1:1 was added a solution of 5-((1-(4-Chlorophenyl)-methanoyl)-amino)-methyl)-thiophene-2-sulfonyl chloride **22b** (1.0g, 2.86 mmol). At the end of addition the suspension disappeared. The reaction mixture was stirred overnight. 100ml EtOAc were added and the excess of amine was extracted with HCl (1N), followed by washings with brine. The organic layers were dried over MgSO<sub>4</sub> and evaporated to dryness to provide **107a** (1.14 g, 99.9%) as a colourless foam: <sup>1</sup>H NMR (DMSO *d*<sub>6</sub>) δ 9.34 (t, *J* = 5.8 Hz, 1H), 7.89 (d, *J* = 8.7 Hz, 2H), 7.49 (d, *J* = 3.8 Hz, 1H), 7.55 (d, *J* = 8.7 Hz, 2H), 7.13 (d, *J* = 3.8 Hz, 1H), 4.95 (d, *J* = 3.4 Hz, 1H), 4.65 (d, *J* = 5.6 Hz, 2H), 4.16 (m, 1H), 3.40-3.20 (m, 5H), 3.00 (m, 1H), 3.35-3.23 (m, 3H), 1.80-1.60 (m, 2H), M/Z APCI: 401.2 (M+1), 398.9 (M-1).

**4-chloro-N-[[5-((3-oxopyrrolidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide, 107b**

**[0124]** At -80°C oxalylchloride (36mg, 0.28mmol) was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub>, while DMSO (50ul, 0.6 mmol) were added slowly. The solution was stirred under Ar for 15minutes. **107a** (100mg, 0.25mmol) was dissolved in 2ml CH<sub>2</sub>Cl<sub>2</sub>, and this solution was added dropwise to the above reaction mixture at -80°C. The reaction was stirred for 15' at low temperature, before DIEA (0.21ml, 1.25mmol) was added. The reaction was stirred at -80°C for 30 minutes and allowed to warm to rt. during 2h. A white solid was formed, the reaction was quenched with water and extracted with CH<sub>2</sub>Cl<sub>2</sub>

several times. The combined organic layers were dried over  $\text{MgSO}_4$  and evaporated to dryness. The crude was purified by flash chromatography on silica gel using EtOAc/cyclohexane 2:1 as eluent. **107b** (80mg, 80%) was obtained as a colourless solid.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.72 (d,  $J = 8.7$  Hz, 2H), 7.46 (d,  $J = 3.8$  Hz, 1H), 7.42 (d,  $J = 8.7$  Hz, 2H), 7.08 (d,  $J = 3.8$  Hz, 1H), 6.59 (t,  $J = 5.8$ , 1H), 4.80 (d,  $J = 6.0$  Hz, 2H), 3.58 (t,  $J = 7.5$  Hz, 2H), 3.50 (s, 3H), 2.54 (t,  $J = 7.5$ , 2H), 3.35-3.23 (m, 3H), 2.95 (m, 2H), 1.94 (m, 2H), 1.86 (m, 2H), 1.70-1.50 (m, 5H), 1.30-1.20 (m, 8H), 0.87 (t,  $J = 6.8$ , 3H), M/Z APCI 399.0 (M+1), 397.2 (M-1)

**4-chloro-N-[(5-[(3-(pentylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide 107**

**[0125]** **107b** was prepared according to example 22 and was isolated as colourless solid in 84% yield (15mg). M/Z APCI: 522.5 (M+1), 520 (M-1). Anal. HPLC: R.t = 4.62 min (method a).

**[0126]** Alternatively **107** can be synthesised in a parallel solution phase approach according to the synthesis described for **22**.

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
<b>108</b>	N-[(5-[(3-(heptylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	4.94	88.3	a	494	492
<b>109</b>	3-methoxy-N-[(5-[(3-(octylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	5.24	100	a	508	506
<b>110</b>	N-[(5-[(3-(butylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	3.97	100.0	a	452	450
<b>111</b>	N-[(5-[(3-(dodecylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	6.34	100.0	a	564	562
<b>112</b>	N-[(5-[(3-[(2-cyclohexylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	4.89	96.5	a	506	504
<b>113</b>	N-[(5-[(3-[(1R)-1-cyclohexylethyl]amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	4.59	100.0	a	506	504
<b>114</b>	N-[(5-[(3-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	4.23	100.0	a	490	488
<b>115</b>	3-methoxy-N-[(5-[(3-[(2-propoxyethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	4.10	100.0	a	482	480
<b>116</b>	N-[(5-[(3-[(cyclohexylmethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	4.49	100.0	a	492	490
<b>117</b>	N-[(5-[(3-[(1-adamantylmethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide	4.99	100.0	a	544	542
<b>118</b>	3-methoxy-N-[(5-[(3-[(3-morpholin-4-ylpropyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide	3.20	100.0	a	523	521

(continued)

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
119	3-methoxy-N-[[5-({3-[(2-pyridin-2-ylethyl)amino]pyrrolidin-1-yl} sulfonyl)thien-2-yl)methyl] benzamide	3.31	100.0	a	501	499
120	3-methoxy-N-[[5-({3-[(2-piperidin-1-ylethyl)amino]pyrrolidin-1-yl} sulfonyl)thien-2-yl)methyl] benzamide	3.32	100.0	a	507	505
121	N-[[5-({3-[(2-ethylhexyl)amino] pyrrolidin-1-yl} sulfonyl)thien-2-yl] methyl]-3-methoxybenzamide	5.04	100.0	a	508	506
122	N-[[5-({3-(hexylamino)pyrrolidin-1-yl} sulfonyl)thien-2-yl)methyl]- 3-methoxybenzamide	4.60	95.2	a	480	478
123	4-chloro-N-[[5-({3-(heptylamino) pyrrolidin-1-yl} sulfonyl)thien-2-yl] methyl]benzamide	5.27	96.4	a	498	496
124	4-chloro-N-[[5-({3-(hexylamino) pyrrolidin-1-yl} sulfonyl)thien-2-yl] methyl]benzamide	5.54	100.0	a	512	510
125	3-methoxy-N-[[5-({3-(pentylamino) pyrrolidin-1-yl} sulfonyl)thien-2-yl] methyl]benzamide	4.28	100	a	466	464
126	N-[[5-({3-(butylamino)pyrrolidin-1-yl} sulfonyl)thien-2-yl)methyl]- 4-chlorobenzamide	4.36	100.0	a	456	454
127	4-chloro-N-[[5-({3-[(2-cyclohexylethyl)amino] pyrrolidin-1-yl} sulfonyl)thien-2-yl] methyl]benzamide	5.16	96.8	a	510	508
128	4-chloro-N-[[5-({3-[(1-hydroxycyclohexyl)methyl] amino}pyrrolidin-1-yl) sulfonyl]thien-2-yl)methyl]benzamide	4.80	100.0	a	496	494
129	N-[[5-({3-[(1-adamantylmethyl) amino]pyrrolidin-1-yl} sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide	5.25	100.0	a	548	546
130	4-chloro-N-[[5-({3-[(3-morpholin-4-ylpropyl)amino]pyrrolidin-1-yl} sulfonyl)thien-2-yl)methyl] benzamide	3.59	100.0	a	527	525
131	4-chloro-N-[[5-({3-[(2-pyridin-2-ylethyl)amino]pyrrolidin-1-yl} sulfonyl)thien-2-yl)methyl] benzamide	3.68	91.9	a	505	503

(continued)

Example	Name	Rt HPLC	Purity	Gradient HPLC	Mass M+1	Mass M
132	4-chloro-N-[[5-[(3-(2-piperidin-1-ylethyl)amino)pyrrolidin-1-yl]sulfonyl]thien-2-yl]methyl]benzamide	3.69	100.0	a	511	509
133	4-chloro-N-[[5-[(3-(2-ethylhexyl)amino)pyrrolidin-1-yl]sulfonyl]thien-2-yl]methyl]benzamide	5.36	100.0	a	512	510
134	4-chloro-N-[[5-[(3-(octylamino)pyrrolidin-1-yl]sulfonyl]thien-2-yl]methyl]benzamide	4.96	91.6	a	484	482

**Example 135: 3-methoxy-N-[[5-[(4-[(pentylamino)methyl]piperidin-1-yl)sulfonyl]thien-2-yl]methyl]benzamide 135*****N-[[5-[(4-(hydroxymethyl)piperidin-1-yl)sulfonyl]thien-2-yl]methyl]-3-methoxybenzamide, 135a***

[0127] To a solution of 4-hydroxymethyl-piperidine (499mg, 4.33 mmol) and DIEA (1.5ml, 8.67mmol) in 15 ml CH<sub>2</sub>Cl<sub>2</sub> was added slowly a solution of 5-[[1-(3-methoxy-phenyl)methanoyl]-amino]-methyl]-thiophene-2-sulfonyl chloride (1.0g, 2.89mmol) in CH<sub>2</sub>Cl<sub>2</sub>/DMF. The reaction mixture was stirred for overnight. 100ml of EtOAc were added and the excess of amines were removed by extraction with HCl (1N). The dried organic layer was evaporated to dryness to provide 1.25 g (99.9%) of pure **135a** as a colourless foam: <sup>1</sup>H NMR (DMSO *d*<sub>6</sub>) δ 9.26 (t, *J* = 5.8 Hz, 1H), 7.55-7.25 (m, 4H), 7.16 (d, *J* = 3.8 Hz, 1H), 7.11 (d, *J* = 9.4 Hz, 1H), 4.66 (d, *J* = 6.0 Hz, 2H), 4.48 (m, 1H), 3.80 (s, 3H), 3.59 (d, *J* = 11.7, 2H), 3.31 (b, m, 1H), 3.20 (d, *J* = 6.0 Hz, 2H), 2.27 (t, *J* = 11.0 Hz, 2H), 1.72 (d, *J* = 11.0 Hz, m, 2H), 1.40-1.0 (m, 4H), M/Z APCI: 425.3 (M+1).

***3-methoxy-N-[[5-[(4-[(pentylamino)methyl]piperidin-1-yl)sulfonyl]thien-2-yl]methyl]benzamide, 135b***

[0128] **135a** (200mg, 0.47mmol) and Triphenylphosphine (247mg, 0.94mmol) were dissolved in dry DMF. To this solution was added at 0°C in small portions N-bromosuccinimide (167mg, 0.94mmol) as a solid. Each portion was added after the yellow color in the solution disappeared. At the end of the addition the yellow color remained and the reaction mixture was heated at 50°C for 90'. The hot reaction is poured into a vial followed by the addition of amylamine (410mg, 4.7mmol). The vial was sealed and heated at 65°C overnight. The reaction mixture was evaporated to dryness and the crude was purified by flash chromatography on silica gel using EtOAc/methanol 10:1 to obtain 180 mg (78%) of **135b** as a colourless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.43-7.25 (m, 4H), 7.05 (m, 2H), 6.75 (m, 1H), 4.82 (d, *J* = 6.0 Hz, 2H), 3.76 (s, 3H), 3.77 (d, *J* = 11.7, 2H), 2.63 (d, *J* = 7.3 Hz, 2H), 2.54 (d, *J* = 6.8 Hz, 2H), 2.35 (t, *J* = 11.1, 2H), 1.85 (d, *J* = 11.1 Hz, m, 2H), 1.70-1.50 (m, 4H), 1.30-1.20 (m, 6H), 0.89 (t, *J* = 6.8, 3H), M/Z APCI: 494.2 (M+1).

**Example 136: Preparation of a pharmaceutical formulation**

[0129] The following formulation examples illustrate representative pharmaceutical compositions according to the present invention being not restricted thereto.

**Formulation 1 - Tablets**

[0130] A sulfonamide compound of formula I is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ration. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active sulfonamide compound per tablet) in a tablet press.

**Formulation 2 - Capsules**

[0131] A sulfonamide compound of formula I is admixed as a dry powder with a starch diluent in an approximate 1:1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active sulfonamide compound per capsule).

Formulation 3 - Liquid

[0132] A sulfonamide compound of formula I (1250 mg), sucrose (1.75 g) and xanthan gum (4 mg) are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously prepared solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg) in water. Sodium benzoate (10 mg), flavor, and color are diluted with water and added with stirring. Sufficient water is then added to produce a total volume of 5 mL.

Formulation 4 - Tablets

[0133] A sulfonamide compound of formula I is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active sulfonamide compound) in a tablet press.

Formulation 5 - Injection

[0134] A sulfonamide compound of formula I is dissolved in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/ml.

Example 137 : Biological assays**Biological Results**

[0135] The activities of the sulfonamide derivatives claimed in the formula I were assessed using the above described *in vitro* and *in vivo* biological assays.

[0136] **JNK 2 and 3 in vitro assays:** JNK3 and/or 2 assays are performed in 96 well MTT plates, by incubation of 0.5 µg of recombinant, pre-activated GST-JNK3 or GST-JNK2 with 1 µg of recombinant, biotinylated GST-c-Jun and 2 µM <sup>33</sup>γ-ATP (2 nCi/µl), in the presence or absence of sulfonamide inhibitors of formula I and in a reaction volume of 50 µl containing 50 mM Tris-HCl, pH 8.0; 10 mM MgCl<sub>2</sub>; 1 mM Dithiothreitol, and 100 µM NaVO<sub>4</sub>. The incubation is performed for 120 min. at R.T and stopped upon addition of 200 µl of a solution containing 250 µg of Streptavidine-coated SPA beads (Amersham, Inc.)\*, 5 mM EDTA, 0.1% Triton X-100 and 50 µM ATP, in phosphate saline buffer. After incubation for 60 minutes at RT, beads are sedimented by centrifugation at 1500 x g for 5 minutes, resuspended in 200 µl of PBS containing 5 mM EDTA, 0.1% Triton X-100 and 50 µM ATP and the radioactivity measured in a scintillation β counter, following sedimentation of the beads as described above.

Example	JNK3	JNK2
1	0.04	nd
22	0.13	0.39
27	0.05	0.61
75	0.26	nd
98	0.56	0.63
116	0.39	0.61
135	0.15	0.46

[0137] The values indicated in respect of JNK2 and 3 refer to the IC<sub>50</sub> (µM), i.e. the amount necessary to achieve 50% inhibition of said target (e.g. JNK2). Said values show a considerable potency of the sulfonamide compounds with regard to JNK3 and JNK2.

**Sympathetic Neuron Culture and Survival Assay**

[0138] Sympathetic neurons from superior cervical ganglia (SCG) of new-born rats (p4) are dissociated in dispase, plated at a density of 10<sup>4</sup> cells/cm<sup>2</sup> in 48 well MTT plates coated with rat tail collagen, and cultured in Leibowitz medium containing 5% rat serum, 0.75 µg/mL NGF 7S (Boehringer Mannheim Corp., Indianapolis, IN.) and arabinosine 10<sup>5</sup>M.

[0139] Cell death is induced at day 4 after plating by exposing the culture to medium containing 10 µg/mL of anti NGF anti-body (Boehringer Mannheim Corp., Indianapolis, IN.) and no NGF or arabinosine, in the presence or absence of sulfonamide inhibitors. 24 hours after cell death induction, determination of cell viability is performed by incubation of the culture for 1 hour, at 37°C in 0.5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)2,5 diphenyl tetrazolium bromide (MTT).

After incubation in MTT cells are resuspended in DMSO, transferred to a 96 MTT plate and cell viability is evaluated by measuring optical density at 590 nm.

[0140] The results of this assay with various test compounds demonstrate that compounds of Formula I are rescuing neurons from cells death (% neurons alive between 10 and 80).

## 5 IL-2 Release Assay:

[0141] Jurkat cells, a human T cell leukemia cell line (American Type Culture Collection # TIB 152) were cultured in RPMI 1640 medium (Gibco, BRL) supplemented with 10% of heat-activated FCS, Glutamine and Penstrep. The cell suspension in the medium is diluted to give  $2.10^6$  cells/mL. The cells were plated ( $2.10^5$  cells/well) on a 96-well plate containing different concentration of test compound (final concentration of compounds, 10, 3, 1, 0.3, 0.1  $\mu$ M). This mixture is incubated 30 minutes at 37°C in a humidified CO<sub>2</sub> atmosphere. Cells were then treated with 10  $\mu$ l PMA + Ionomycin (0.1  $\mu$ M and 1  $\mu$ M final concentration) in all wells except negative control. In wells without compounds, 10  $\mu$ l of RPMI 2% DMSO (=0.1% final) is added. Cells are incubated 24 hours at 37°C and then the supernatant harvested (freeze at -20°C if not used the same day) prior to performing IL-2 ELISA test on the supernatant.

## 15 IL-2 ELISA Assay:

[0142] IL-2 release into the medium by PMA+Iono-stimulated Jurkat cells, in presence or absence of test compounds is assayed by ELISA. Following the procedure described below

### 20 Solutions

Wash buffer: PBS- Tween 0.05%

Diluent: PBS- Tween 0.05%

Substrate solution: Citric acid 0.1M/Na<sub>2</sub>HPO<sub>4</sub> 0.1M

Stop solution: H<sub>2</sub>SO<sub>4</sub> 20%

### 30 Matched Antibody pairs/standard:

From R&D Systems

Monoclonal anti-human IL-2 antibody (MAB602) (capture)

Biotinylated anti-human IL-2 antibody (BAF202) (detection)

Recombinant human IL-2 (202-IL-010) (standard)

### 35 Plate preparation

Transfer 100  $\mu$ l capture antibody diluted in PBS at 5  $\mu$ g/mL into a 96 well ELISA plate and incubate overnight at room temperature.

Aspirate each well and wash 3 times with Wash buffer. After the last wash, damp the plate.

1. Saturate with 200  $\mu$ l PBS-10% FCS. Incubate 1 hour at room temperature.

2. Repeat the wash step 2.

### 45 Assay procedure

1. Add 100  $\mu$ l of sample or standard (2000, 1000, 500, 250, 125, 62.5, 31.25pg/mL) and incubate 2 hours at room temperature.

2. Wash 3 times.

3. Add 100  $\mu$ l of biotinylated anti-human IL-2 at 12.5 ng/mL. Incubate 2 hours at room temperature.

4. Wash 3 times.

5. Add 100  $\mu$ l streptavidin-HRP (Zymed #43-4323) at 1:10'000. Incubate 30 minutes at room temperature.

6. Wash 3 times

7. Add 100  $\mu$ l substrate solution (citric acid/Na<sub>2</sub>HPO<sub>4</sub> (1:1) + H<sub>2</sub>O<sub>2</sub> 1:2000 + OPD). Incubate 20-30 minutes at room temperature.

8. Add 50  $\mu$ l of stop solution to each well.

9. Determine optical density using a microtiter plate reader set to 450 nm with correction at 570 nm.

[0143] The result of this assay shows that various test compounds decrease the production of IL-2 of more than 30%

at 3  $\mu$ M.

## C-Jun Reporter Assay

### 5 Cell culture

[0144] Hlr c-Jun HeLa cells are cultured in DMEM High Glc supplemented with 10% FCS (Sigma), 2mM Glutamine (Gibco), P/S, Hygromycin b 100 $\mu$ g/mL and G418 250 $\mu$ g/mL

### 10 Cell culture preparation

#### Cell Banks

[0145] The cells are stored frozen in cryotubes under liquid nitrogen, as 1.8 mL volumes of cell suspension in culture medium containing 10% dimethyl sulfoxide.  
Cells are kept in culture for no more than 20 passages.

#### Cell culture thawing

[0146] When necessary, frozen vials of cells are thawed rapidly at 37°C in a water bath by gently swirling up to semi-complete thawing. Then the cell suspension are added to 10 mL of culture medium.  
The cell suspension is then centrifuged for 5 minutes at 1200 rpm, the supernatant is removed and the cell pellet reconstituted in the medium and add to a 175 cm<sup>2</sup> flask containing 25 mL medium. The flasks are incubated at 37° C in an atmosphere of 5 % CO<sub>2</sub>.

### 25 Cell passage

[0147] The cells are serially subcultured (passaged) when 80% confluent monolayers have been obtained.  
The medium of each flask is removed and the monolayer is washed with 10-15 mL of phosphate buffer solution (PBS).  
[0148] Trypsin-EDTA solution is added to the cell monolayer, incubated at 37° C and tapped gently at intervals to dislodge the cells. Complete detachment and disaggregation of the cell monolayer is confirmed by microscopy examination.  
The cells are then resuspended in 10 mL of complete medium and centrifuged for 5 minutes at 1200 rpm.  
The supernatant are discarded, the cells are resuspended in culture medium and diluted 1/5 in 175 cm<sup>2</sup> flasks.

### 35 Day 0 morning

#### Prepare cells for transfections

[0148] The cells from flasks of near-confluent cultures are detached and disaggregated by treatment with trypsin as described above.  
[0149] The cells are resuspended in culture medium and counted.  
The cell suspension are diluted with medium to give about 3.5x10<sup>6</sup> cells/mL and 1 mL  $\mu$ l of cell suspension are put onto 2 10cm culture dishes containing 9 mL of culture medium.  
The plates are incubated at 37° C in a humidified atmosphere of 5 % CO<sub>2</sub> in air.

### 45 Day 0 evening

#### [0150] Transfections

50	Control	0.2 $\mu$ g pTK Renilla, 5.8 $\mu$ g pBluescript KS, 500 $\mu$ l OPTIMEM (GIBCO), 18 $\mu$ l Fugene 6
	Induced	0.1 $\mu$ g pMEKK1, 0.2 $\mu$ g pTK Renilla, 5.7 $\mu$ g pBluescript KS, 500 $\mu$ l OPTIMEM (GIBCO), 18 $\mu$ l Fugene 6 30' RT

55 The transfection mixture is added to the plated cells. The plates are incubated over night at 37° C in a humidified atmosphere of 5 % CO<sub>2</sub> in air.

**Day 1**

[0151] A 96 wells plate containing 100 µl of culture medium per well is prepared

- 5 Negative control (vehicle): 2µl of DMSO is added to the 100µl(in triplicate).  
Compound : 2 µl of Hit compound stock dilution are added to the 100µl(in triplicate).

The transfected cells are trypsinised and resuspend in 12 mL of culture medium. 100µl of the dilution are added to each of the 96 wells plate.

10 The plate is incubated over night at 37° C in a humidified atmosphere of 5 % CO<sub>2</sub> in air

**Hit compound dilutions**

[0152] Hit compound stock concentrations are the following:

15 3, 1 and 0.1mM in 100% DMSO.

**Day 2**

**Test procedure**

20 Dual-Luciferase™ Reporter Assay System (Promega)

[0153] The medium is removed from the plate and the cells washed two times with 100µl PBS Completely remove the rinse solution before applying PLB reagent. Dispense into each culture well 5µl of 1X PLB. Place the culture plates on a rocking platform or orbital shaker with gentle rocking/shaking to ensure complete and even coverage of the cell monolayer with 1X PLB. Rock the culture plates at room temperature for 15 minutes. Transfer 20 µl of the lysate into a white opaque 96 wells plate. Read in a luminometer.

- 30 - Inject 50µl of Luciferase Assay Reagent II wait 5", read 10"  
- Inject 50µl of Stop & Glo ® Reagent wait 5", read 10"

Check RLU Luciferase/RLU Renilla\*1000

[0154] The result of this assay shows that various test compounds inhibit more than 20% of the activity of JNK at 10 µM.

**LPS induced endotoxin shock in mice**

[0155] *The ability of the JNK inhibitors described in formula I to significantly reduce the level of inflammatory cytokines induced by LPS challenge was assessed using the following protocol:*

40 LPS (S. abortus-Galanos Lab.-) was injected (200 µg/kg, i.v.) to Male C57BL/6 to induce endotoxin shock and compounds (0.1, 1, 10 mg/kg) or NaCl (200µM) were injected intravenously (10 mL/kg) 15 min before the LPS challenge. Heparinized blood was obtained from the orbital sinus at different time points after the LPS challenge, and the blood was centrifuged at 9'000 rpm for 10 min at 4° C to collect supernatant for the measurement of cytokines production by mouse ELISA kit such as IFNγ (DuoSet R&D Ref. DY485).

**Global Ischemia in Gerbils**

[0156] *The ability of the JNK inhibitors described in formula I to protect cell death during a stroke event was assessed using the following protocol:*

**-1- METHOD**

[0157]

**\* Surgery**

- Anesthesia: halothane or isoflurane (0.5-4%).

- Sheaving of the gorge and incision of the skin.
- The common carotid arteries (left and right) are freed from tissue.
- Occlusion of the arteries using Bulldog microclamps during 5 min.
- Disinfection of the surgery plan (Betadine®) and suture of the skin (Autoclip® ou Michel's hooks).
- Stabulation of the animals under heating lamp until awake.
- Stabulation of the animals in the animalry in individual cages.

\* Sacrifice of the animals

- 7 days after ischemia (Decapitation or overdose of pentobarbital).
- Sampling of the brain.

\* Histological parameters

- Freezing of the brain in isopentane (-20°C)
- Slicing of the hippocampus using a cryo-microtome (20 µm).
- Staining with cresyl violet and/or TUNEL method
- Evaluation of the lesions (in CA1/CA2 subfields of the hippocampus)

- Gerhard & Boast score modified or
- Cell counting in the CA1/CA2

\* Biochemical parameters

- Microdissection of the cerebral structures
- Parameters determined: DNA fragmentation, lactate, calcium penetration.
- Analytical methods: ELISA, colorimetry, enzymology, radiometry.

**-2- TREATMENT**

**[0158]**


- Administration of the test article or the vehicle: 15 min after reperfusion (5-10 min after the recovery of the anesthesia).
- Standard protocol

50 animals : 5 groups of 10 (group A : control, groups B-D : test article at 3 doses and group E : reference compound (ketamine 3x120 mg/kg, *ip* or Orotic acid 3x300 mg/kg, *ip*).

**[0159]** The test compounds displayed considerable capability to protect from neuronal apoptosis during induced global ischemia.

**Claims**

1. Sulfonamide derivatives according to formula I



**I**

with its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Ar<sup>1</sup> and Ar<sup>2</sup> are independently from each other substituted or unsubstituted aryl or heteroaryl groups,

X is O or S, preferably O;

R<sup>1</sup> is hydrogen or a C<sub>1</sub>-C<sub>6</sub>-alkyl group, or R<sup>1</sup> forms a substituted or unsubstituted 5-6-membered saturated or

Y is a 4-12-membered saturated cyclic or bicyclic alkyl containing a nitrogen, which forms a bond with the sulfonyl group of formula I, said 4-12-membered saturated cyclic or bicyclic alkyl is substituted with at least one ionisable moiety to which a lipophilic chain is attached.

- whereby R<sup>6</sup> is selected from the group comprising or consisting of hydrogen, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxy, OH, halogen, nitro, cyano, sulfonyl, oxo (=O), sulfoxy, acyloxy, thioalkoxy and where R<sup>6</sup> is not hydrogen, n' is an integer from 0 to 4, preferably 1 or 2, whereby at least one of L<sup>1</sup> and/or L<sup>2</sup> is an ionisable moiety to which a lipophilic chain is attached.

- L<sup>1</sup> is -NHR<sup>3</sup>; where R<sup>3</sup> is a straight or branched C<sub>6</sub>-C<sub>12</sub>-alkyl, preferably a C<sub>8</sub>-C<sub>12</sub>-alkyl.

- 3-methoxy-N-({5-[(4-{[4-(trifluoromethyl)benzyl]amino} piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide**

- 4-chloro-N-[[5-({4-[(3-chlorobenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(4-methoxybenzyl)piperazin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(4-(trifluoromethyl)sulfanyl]benzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 5 3-methoxy-N-[[5-({4-[(4-phenoxybenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(4-(trifluoromethyl)sulfonyl]benzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(3-methylbenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(4-propylbenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 10 3-methoxy-N-[[5-({4-[(3-(trifluoromethyl)benzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(4-(trifluoromethoxy)benzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(4-(difluoromethoxy)benzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-[(2,3,4,5,6-pentamethylbenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 15 3-methoxy-N-[[5-({4-[(4-propoxybenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(4-butoxybenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-[(4-methoxybenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(pyridin-4-ylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(pyridin-2-ylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 20 3-methoxy-N-[[5-({4-[(pyridin-3-ylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(quinolin-4-ylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(4-tert-butylbenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(3-ethoxybenzyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 25 4-chloro-N-[[5-({4-[(hexylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(heptylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(pentylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(butylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(dodecylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 30 4-chloro-N-[[5-({4-[(2-cyclohexylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(cyclohexylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(1R)-1-cyclohexylethyl]amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide  
 35 4-chloro-N-[[5-({4-[(2-propoxyethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(1-adamantylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide  
 4-chloro-N-[[5-({4-[(2-pyridin-2-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(2-piperidin-1-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(2-ethylhexyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 4-chloro-N-[[5-({4-[(octylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 40 N-[[5-({4-[(heptylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-[(octylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(pentylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(butylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(dodecylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 45 3-methoxy-N-[[5-({4-[(nonylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(decylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(ethylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(2-cyclohexylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(1R)-1-cyclohexylethyl]amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 50 N-[[5-({4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[[5-({4-[(2-propoxyethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(1-adamantylmethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 N-[[5-({4-[(3,3-diethoxypropyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide  
 55 3-methoxy-N-[[5-({4-[(3-morpholin-4-ylpropyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(2-pyridin-2-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 3-methoxy-N-[[5-({4-[(2-piperidin-1-ylethyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide  
 N-[[5-({4-[(2-ethylhexyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide

N-({5-({4-(hexylamino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 3-methoxy-N-({5-({4-({2-({3-(trifluoromethyl)phenyl)ethyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({2-(4-methylphenyl)ethyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 5 3-methoxy-N-({5-({4-({4-(trifluoromethyl)benzyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({(1S,2R)-2-phenylcyclopropyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({1-naphthylmethyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({2-phenylpropyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 10 N-({5-({4-({2-(4-hydroxyphenyl)ethyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 3-methoxy-N-({5-({4-({3-phenylpropyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 N-({5-({4-({2,3-dihydroxypropyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 N-({5-({4-({2-hydroxyethyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 N-({5-({4-({2-1,1'-biphenyl-4-ylethyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 15 N-({5-({4-({1,1'-biphenyl-3-ylmethyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 3-methoxy-N-({5-({4-({2-thien-2-ylethyl}amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 5-({3-methoxybenzoyl}amino)methyl}-2-({4-(octylamino)piperidin-1-yl)sulfonyl}thiophene-3-carboxylic acid  
 N-({5-({4-(heptylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 3-methoxy-N-({5-({4-(octylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 20 3-methoxy-N-({5-({4-(pentylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 N-({5-({4-(butylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 N-({5-({4-(dodecylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 N-({5-({4-({2-cyclohexylethyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 N-({5-({4-({3-(1H-imidazol-1-yl)-1-cyclohexylethyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 25 N-({5-({4-({1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 3-methoxy-N-({5-({4-({2-propoxyethyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 N-({5-({4-({cyclohexylmethyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 N-({5-({4-({1-adamantylmethyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 30 3-methoxy-N-({5-({4-({3-morpholin-4-ylpropyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({2-pyridin-2-ylethyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 3-methoxy-N-({5-({4-({2-piperidin-1-ylethyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 N-({5-({4-({2-ethylhexyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 N-({5-({4-({3-(1H-imidazol-1-yl)propyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 35 4-chloro-N-({5-({4-(heptylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 4-chloro-N-({5-({4-(octylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 4-chloro-N-({5-({4-(pentylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 N-({5-({4-(butylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-4-chlorobenzamide  
 4-chloro-N-({5-({4-(dodecylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 40 4-chloro-N-({5-({4-({2-cyclohexylethyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 N-({5-({4-({1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-4-chlorobenzamide  
 4-chloro-N-({5-({4-({2-propoxyethyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 4-chloro-N-({5-({4-({2-ethylhexyl}amino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 45 4-chloro-N-({5-({4-(hexylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 N-({5-({4-(hexylamino)azepan-1-yl)sulfonyl})thien-2-yl)methyl}-3-methoxybenzamide  
 4-chloro-N-({5-({4-({hexyl(pyridin-2-ylmethyl)amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 4-chloro-N-({5-({4-({cyclohexylmethyl}(hexyl)amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 N-({5-({4-({benzyl(hexyl)amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}-4-chlorobenzamide  
 50 4-chloro-N-({5-({4-({hexyl(pyridin-3-ylmethyl)amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 4-chloro-N-({5-({4-({hexyl(pyridin-4-ylmethyl)amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 N-({5-({4-({5-bromo-2-furyl)methyl}(hexyl)amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}-4-chlorobenzamide  
 N-({5-({4-({butyl(hexyl)amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}-4-chlorobenzamide  
 55 4-chloro-N-({5-({4-({hexyl(3-phenylpropyl)amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 4-chloro-N-({5-({4-({hexyl(2-phenylethyl)amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 4-chloro-N-({5-({4-({hexyl(methyl)amino)piperidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide  
 4-chloro-N-({5-({3-(pentylamino)pyrrolidin-1-yl)sulfonyl})thien-2-yl)methyl}benzamide

N-[(5-[(3-(heptylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[(5-[(3-(octylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(3-(butylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(3-(dodecylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(3-[(2-cyclohexylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(3-[(1R)-1-cyclohexylethyl]amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(3-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[(5-[(3-[(2-propoxyethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(3-[(cyclohexylmethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(3-[(1-adamantylmethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 3-methoxy-N-[(5-[(3-[(3-morpholin-4-ylpropyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 3-methoxy-N-[(5-[(3-[(2-pyridin-2-ylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 3-methoxy-N-[(5-[(3-[(2-piperidin-1-ylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(3-[(2-ethylhexyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 N-[(5-[(3-(hexylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide  
 4-chloro-N-[(5-[(3-(heptylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(3-(hexylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 3-methoxy-N-[(5-[(3-(pentylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(3-(butylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide  
 4-chloro-N-[(5-[(3-[(2-cyclohexylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(3-[(1-hydroxycyclohexyl)methyl]amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 N-[(5-[(3-[(1-adamantylmethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide  
 4-chloro-N-[(5-[(3-[(3-morpholin-4-ylpropyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(3-[(2-pyridin-2-ylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(3-[(2-piperidin-1-ylethyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(3-[(2-ethylhexyl)amino]pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 4-chloro-N-[(5-[(3-(octylamino)pyrrolidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide  
 3-methoxy-N-[(5-[(3-(pentylamino)methyl]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide

11. A sulfonamide derivative according to any of the preceding claims for use as a medicament.

12. Use of a sulfonamide derivative according to any of claims 1 to 10 for the preparation of a pharmaceutical composition for the modulation of the JNK pathway.

13. Use according to claim 12 for the treatment or prevention of disorders associated with the abnormal expression or activity of JNK.

14. Use according to claim 13 for the treatment or prevention of disorders associated with abnormal expression or activity of JNK2 and/or 3.

15. Use of a sulfonamide according to formula I in particular according to any of claims 12 to 14 for the treatment of neuronal disorders including epilepsy; Alzheimer's disease, Huntington's disease, Parkinson's disease; retinal diseases, spinal cord injury, head trauma.


16. Use of a sulfonamide according to formula I in particular according to any of claims 12 to 14 for the treatment of autoimmune diseases including Multiple Sclerosis, inflammatory bowel disease (IBD), rheumatoid arthritis, asthma, septic shock, transplant rejection.

17. Use of a sulfonamide according to formula I in particular according to any of claims 12 to 14 for the treatment of cancer including breast-, colorectal-, pancreatic cancer.

18. Use of a sulfonamide according to formula I in particular according to any of claims 12 to 14 for the treatment of cardiovascular diseases including stroke, arterosclerosis, myocardial infarction, myocardial reperfusion injury.


19. A pharmaceutical composition containing at least one sulfonamide derivative according to any of the claims 1 to 10 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

20. Process for the preparation of a sulfonamide derivative according to any of claims 1 to 10, wherein a sulfonyl chloride V




V

is reacted with a cyclic amide, in particular with any of the amines VIII, VIII' and VIII''




VIII'' or



VIII'

or



VIII

whereby  $(\text{R}^6)_n$ ,  $\text{L}^1$  and  $\text{L}^2$  are as above defined.


21. A process according to claim 21, wherein a sulfonyl chloride V is obtainable by

a) coupling an amine of formula II:




II

where  $\text{Ar}^2$  and  $\text{R}^1$  are as defined above, with an acyl chloride of formula III:




III

where  $\text{Ar}^1$  is as defined above, to provide an amide of formula IV:



IV

b) sulfonating the amide of formula IV to provide a sulfonyl chloride V



V



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 00 81 0887

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 97 45403 A (LIN CHIU HONG ;UPJOHN CO (US); LEIBY JEFFREY A (US); ROMERO ARTHUR) 4 December 1997 (1997-12-04)	1	C07D409/12 A61K31/4535 A61K31/55
Y	* abstract; claims * * page 44 - page 45; example 72 *	11,15,16	A61K31/4025 A61P25/00 A61P25/16
X	WO 98 53814 A (MERCK & CO., INC., USA) 3 December 1998 (1998-12-03)	1	A61P11/06 C07D333/34 C07D409/14 C07D413/14
Y	* abstract; claims 1,5,13,15 * * page 44; examples 134,136 * * page 45; example 164 * * page 43; example 128 *	11,15,16	
X	MATTER, HANS ET AL: "Affinity and Selectivity of Matrix Metalloproteinase Inhibitors: A Chemometrical Study from the Perspective of Ligands and Proteins" J. MED. CHEM. (1999), 42(22), 4506-4523 , XP002162629 * page 4508 - page 4511; table 1 * * page 4510; example 41 *	1	
X	MATTER, HANS ET AL: "Quantitative Structure-Activity Relationship of Human Neutrophil Collagenase (MMP-8) Inhibitors Using Comparative Molecular Field Analysis and X-ray Structure Analysis" J. MED. CHEM. (1999), 42(11), 1908-1920 , XP002162630 * page 1909 - page 1912; table 1 *	1	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C07D A61K A61P
X	US 5 238 950 A (CLADER, JOHN W. ET AL) 24 August 1993 (1993-08-24) * abstract; claims 1,10 * * column 13; example 1P *	1	
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>12 March 2001</b>	Examiner <b>Paisdor, B</b>
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>&amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 62 (P04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 00 81 0887

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	<p>DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GRIGORYAN, L. A. ET AL: "Arylsulfonic acid derivatives. XVII. Synthesis of N-'.gamma.-(N,N-disubstituted sulfamoylphenyl)alkyl-4- alkoxybenzamides" retrieved from STN Database accession no. 112:118396 XP002162631 * abstract; figures 21-24 * &amp; ARM. KHIM. ZH. (1989), 42(4), 236-40 ,</p>	1	
X	<p>--- DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NEW, A. P. ET AL: "A comparison of positive ion and negative ion fast atom bombardment mass spectral data for some sulfonyl hydrazones and derivatives" retrieved from STN Database accession no. 111:189437 XP002162632 * abstract; figures 25-27 * &amp; BIOMED. ENVIRON. MASS SPECTROM. (1989), VOLUME DATE 1988, 18(8), 620-3 ,</p> <p>--- -/--</p>	1	
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>12 March 2001</b>	Examiner <b>Paisdor, B</b>
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 82 (p04c01)



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 00 81 0887

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	<p>DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KALDRIKYAN, M. A. ET AL: "Synthesis and chemotherapeutic activity of new p-sulfamoylbenzyl (phenethyl) amides of benzofuran-2-carboxylic acid in staphylococcal infection" retrieved from STN Database accession no. 100:209560 XP002162633 * abstract; figures 28-30 * &amp; KHIM.-FARM. ZH. (1984), 18(1), 58-61 ,</p>	1	
X	<p>DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CREMLYN, RICHARD ET AL: "Chlorosulfonation of N-benzyl carboxamides" retrieved from STN Database accession no. 112:178264 XP002162634 * abstract; figures 17-20 * &amp; PHOSPHORUS, SULFUR SILICON RELAT. ELEM. (1989), 44(3-4), 167-75 ,</p>	1	
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>12 March 2001</b>	Examiner <b>Paisdor, B</b>
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>	

EPO FORM 1503 03 82 (Pct-C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 81 0887

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-03-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9745403 A	04-12-1997	AU 720414 B	01-06-2000
		AU 3060197 A	05-01-1998
		CN 1217711 A	26-05-1999
		CZ 9803701 A	12-05-1999
		EP 0923542 A	23-06-1999
		FI 982572 A	27-11-1998
		JP 2000511529 T	05-09-2000
		NO 985599 A	30-11-1998
		PL 330207 A	26-04-1999
		SK 148898 A	13-03-2000
		US 6084130 A	04-07-2000
WO 9853814 A	03-12-1998	EP 1001764 A	24-05-2000
US 5238950 A	24-08-1993	NONE	

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82